This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Choi, J.-H. Articles by Leung, P. C. K. Search for Related Content PubMed PubMed Citation Articles by Choi, J.-H. Articles by Leung, P. C. K.

Gonadotropins and Ovarian Cancer

Department of Obstetrics and Gynecology (H.-F.H., P.C.K.L.), Zhejiang University School of Medicine, Zhejiang 310016, China; Department of Zoology (A.S.T.W.), University of Hong Kong, Hong Kong; and Department of Obstetrics and Gynecology (J.-H.C., P.C.K.L.), University of British Columbia, Child and Family Research Institute, Vancouver, British Columbia, Canada V6H 3V5

Correspondence: Address all correspondence and requests for reprints to: Peter C. K. Leung, Ph.D., Department of Obstetrics and Gynecology, University of British Columbia, 2H-30, 4490 Oak Street, Vancouver, British Columbia, Canada V6H 3V5. E-mail: peleung{at}interchange.ubc.ca

	Abstract

Top Abstract I. Introduction II. Biology of Ovarian... III. Gonadotropin Theory IV. Action of Gonadotropins... V. Clinical Applications VI. Conclusion and Future... References

 
Ovarian epithelial cancer (OEC) accounts for 90% of all ovarian cancers and is the leading cause of death from gynecological cancers in North America and Europe. Despite its clinical significance, the factors that regulate the development and progression of ovarian cancer are among the least understood of all major human malignancies. The two gonadotropins, FSH and LH, are key regulators of ovarian cell functions, and the potential role of gonadotropins in the pathogenesis of ovarian cancer is suggested. Ovarian carcinomas have been found to express specific receptors for gonadotropins. The presence of gonadotropins in ovarian tumor fluid suggests the importance of these factors in the transformation and progression of ovarian cancers as well as being prognostic indicators. Functionally, there is evidence showing a direct action of gonadotropins on ovarian tumor cell growth. This review summarizes the key findings and recent advances in our understanding of these peptide hormones in ovarian cancer development and progression and their role in potential future cancer therapy. We will first discuss the supporting evidence and controversies in the "gonadotropin theory" and the use of animal models for exploring the involvement of gonadotropins in the etiology of ovarian cancer. The role of gonadotropins in regulating the proliferation, survival, and metastasis of OEC is next summarized. Relevant data from ovarian surface epithelium, which is widely believed to be the precursor of OEC, are also described. Finally, we will discuss the clinical applications of gonadotropins in ovarian cancer and the recent progress in drug development.

I. Introduction

II. Biology of Ovarian Epithelial Cancer (OEC)

A. Etiology and pathogenesis

B. Ovarian surface epithelium (OSE)

III. Gonadotropin Theory

A. Epidemiological evidence

B. Animal models

C. Gonadotropin levels in patients with OEC

D. Expression of gonadotropin receptors in OSE and OEC cells

IV. Action of Gonadotropins in OSE and OEC Cells

A. Gonadotropin-regulated gene expression

B. Proliferation

C. Apoptosis

D. Invasion and angiogenesis

V. Clinical Applications

A. Diagnostic and prognostic factor

B. Hormone therapy

C. Drug development

VI. Conclusion and Future Directions

	I. Introduction

Top Abstract I. Introduction II. Biology of Ovarian... III. Gonadotropin Theory IV. Action of Gonadotropins... V. Clinical Applications VI. Conclusion and Future... References

 
GONADOTROPINS, FSH and LH, belong to a family of glycoprotein hormones along with human placental chorionic gonadotropin (hCG) and TSH. FSH and LH are synthesized in the anterior pituitary and share similar chemical and structural features. Both hormones are key regulators of reproduction, and they act in an endocrine manner to regulate steroidogenesis and gametogenesis in the ovary and testis. The actions of FSH and LH on granulosa and theca cells have been well characterized and are essential for follicular development (1, 2). In addition, there is increasing evidence suggesting that it is the hormonal environment of the normal ovarian surface epithelium (OSE) and ovarian epithelial cancer (OEC) cells that is associated with the development and progression of ovarian cancer. Exposure to excess gonadotropins, related to menopause, ovulation, or infertility therapy, has been implicated as an important possible risk factor for ovarian cancer. However, the exact role of gonadotropins and its molecular mechanism in OSE and OEC has not been fully characterized.

	II. Biology of Ovarian Epithelial Cancer (OEC)

Top Abstract I. Introduction II. Biology of Ovarian... III. Gonadotropin Theory IV. Action of Gonadotropins... V. Clinical Applications VI. Conclusion and Future... References

 
A. Etiology and pathogenesis
Ovarian cancer is the sixth most common cancer and the fifth leading cause of cancer-related death among women in developed countries. Worldwide, the total number of cases is approximately 190,000 per year (3). Due to the absence of specific symptoms and signs and the lack of trustworthy screening for the early detection of ovarian malignancies, the majority of women with ovarian cancer (60–65%) are diagnosed at a late stage when the cancer has spread beyond the confines of the ovary. Most patients presenting in FIGO (International Federation of Gynecology and Obstetrics) stages III and IV have shown a 5-yr survival of around 28 and 16%, respectively. In contrast, the 5-yr survival rate is close to 80% for patients in stage I (4, 5).

The etiology of ovarian cancer remains poorly understood. Epidemiological studies have failed to yield a consensus regarding the contribution of chemical carcinogens to the development of ovarian cancer. Recent studies have linked tobacco products/smoking to an increased incidence of the mucinous type of ovarian cancer (6, 7, 8). In addition, talc (9, 10), asbestos (11), and alcohol (12) have been sometimes associated with an increased risk. However, these issues are limited by inconsistent data and/or the lack of supportive animal models. Other factors include a family history (13). In addition, hormonal and/or reproductive factors such as nulliparity and infertility have been consistently recognized as risk factors of ovarian cancer, whereas pregnancy, oral contraceptive (OC) use, hysterectomy, and tubal ligation have protective effects on ovarian cancer (14). Women suffering from infertility have about a 2-fold higher ovarian cancer risk than does the general population (14). Ovulation induction agents used in the treatment of infertility (clomiphene or gonadotropins) may also be a risk factor for ovarian cancer (15, 16, 17, 18, 19). Interestingly, each additional pregnancy after the first also decreases the risk 10–16% (20, 21). The reduction of ovarian cancer risk in women ever taking OC compared with nonusers is about 30% (22, 23, 24), and tubal ligation and hysterectomy, without oophorectomy, also reduced the risk of ovarian cancer. This is presumably due to decreased exposure of the ovary to potential carcinogen factors and/or inflammation (25, 26, 27).

There are many types of tumors that can start in the ovaries, including germ cell tumors, sex cord-stromal tumors, and epithelial tumors. Ovarian germ cell tumors develop from primitive germ cells of the embryonic gonad, and the most common germ cell malignancies are dysgerminoma, teratoma, and yolk sac tumor. Sex cord-stromal neoplasms arise from various cell types in gonadal stroma and sex cords. Granulosa cell tumors (GCT) are the most prevalent tumor in this group, which constitutes of approximately 5% of all ovarian cancers. In addition to estrogen synthesis (28) and secretion of the gonadal peptide hormones (29), GCT has been found to express gonadotropin receptor (30, 31) and response to gonadotropins (32, 33, 34). In this regard, it has been speculated that gonadotropin may be involved in the pathogenesis of GCT. Approximately 90% of malignant ovarian tumors are epithelial tumors and arise from the OSE. Interestingly, the simple primitive OSE with mesenchymal features acquires the characteristics of Müllerian epithelium as it develops to malignancy (35). In fact, based on the morphological, functional, and antigenic resemblance to epithelium of Müllerian ducts, this disease is divided into a number of subtypes, including serous (fallopian tube), mucinous (endocervical-like), and endometrioid (endometrium-like) tumors (35, 36).

B. Ovarian surface epithelium (OSE)
The OSE is a single layer of flat-to-cuboidal epithelial cells covering the ovary (37). Studies on the ovary have mainly focused on the other cell types such as granulosa and theca cells, which play a critical role in folliculogenesis and steroidogenesis. The OSE was among the least studied part of the ovary due to its inconspicuous histological appearance and apparent lack of significant functions. Interest in the OSE began when it became apparent that OSE might be the tissue of origin of the OEC (38, 39). However, the cellular and molecular mechanisms by which OSE cells undergo tumor formation and neoplastic progression are still not well understood.

The OSE is separated from the hormone/growth factor-producing stroma by the collagenous tunica albuginea and a basement membrane. Ovulation and aging-related trapping of OSE fragments result in surface invaginations (clefts) and inclusion cysts in the ovarian cortex (40). Numerous studies have provided direct evidence bearing on the frequent metaplasia and neoplastic conversion of the clefts and inclusion cysts, possibly because of the aberrant exposure to the hormone/growth factor-rich stromal microenvironment (41, 42, 43, 44). Thus, the OSE trapped into the ovarian cortex has been generally considered as a neoplastic progression-prone site for OEC. However, whether the surface and/or cyst epithelial cells directly progress to a malignant neoplasm is still not clear. Ness and Cottreau (11) have suggested that it is an inflammatory microenvironment such as cell damage, oxidative stress, and elevations of cytokines and prostaglandins, rather than the trapping of the OSE into the stroma, that could mediate the mutagenesis induced by ovarian ovulation. Repetitive loss of the basement membrane, during ovulation, has been implicated as an early event in the preneoplastic transformation of OSE. This may be mediated through enhanced survival of the epithelial cells and/or preferential selection of apoptosis-resistant cells (45, 46, 47).

More recently, there is the "stem cell niche" concept for cancer development (48). Somatic stem cells appear to reside within a specialized area, or niche, where they could remain quiescent until activation by an injury or other stimulation. Adult OSE cells have the stem cell property of self-renewal, which makes them candidates for this new concept. It is also noteworthy that the OSE is closer in its differentiation state to the pluripotent or multipotent mesodermal embryonic precursor cells than other epithelial derivates (49, 50). As discussed above, OSE is a simple, rather primitive epithelium with some stromal features, but as it progresses to malignancy it loses stromal characteristics and acquires the characteristics of the complex glandular epithelial phenotypes of Müllerian duct-derived tissues. This retention of pluripotentiality may be accompanied by greater proliferative capacity with reduced induction of apoptotic cell death pathways and therefore perhaps enhanced the susceptibility to neoplastic transformation. Many signal molecules have been shown to be involved in regulation of stem cell behavior, including hormones/growth factors, Wnt, Notch, and sonic hedgehog, in various organ systems (51, 52, 53, 54, 55). In the ovary, gonadotropins are involved in the regulation of cell proliferation, apoptosis, and differentiation. Whether they would play any role in the OSE stem cell niche remains to be elucidated and is an area for further research.

	III. Gonadotropin Theory

Top Abstract I. Introduction II. Biology of Ovarian... III. Gonadotropin Theory IV. Action of Gonadotropins... V. Clinical Applications VI. Conclusion and Future... References

 
To date, several hypotheses have been suggested to explain the etiology of ovarian cancer. Five will be mentioned here. One is the incessant ovulation hypothesis. The second is the inflammation hypothesis, and the third is the stromal hypothesis. The fourth is the androgen/progesterone hypothesis, and the fifth is the gonadotropin hypothesis.

The incessant ovulation hypothesis, which was initially proposed by Fathalla (56) in 1971 and later extended by other researchers (57), is that repeated trauma during ovulation leads to an increased exposure of the OSE to genetic abnormalities and/or other risk factors. Indeed, early menarche, late menopause, and nulliparity, all of which have more ovulation episodes, increase the risk of developing ovarian cancer. On the other hand, conditions in which ovulation is suppressed, such as multiple pregnancies and prolonged breastfeeding, have been reported to lower the risk to develop ovarian cancer (58, 59, 60). Although this incessant ovulation theory reconciles with certain epidemiological and experimental data, the underlying mechanism remains poorly understood. Moreover, it fails to provide an explanation for the decreased ovarian cancer risk associated with twin pregnancies (61), the increased risk of ovarian cancer among women with obesity (62, 63, 64, 65), and polycystic ovary syndrome (PCOS) (66) Alternative complementary, not mutually exclusive, hypotheses of the incessant ovulation theory have been proposed. The inflammation hypothesis was advocated based on an increased incidence of ovarian cancer among individuals with pelvic inflammatory disease along with the interesting possibility that hysterectomy and tubal ligation could prevent ovarian cancer (12). Endometriosis, which causes a marked local inflammatory reaction, has been linked to ovarian cancer, in particular endometrioid and clear cell histotypes, in a variety of epidemiological and clinical studies. It is also associated with decreased fertility and general endocrine dysfunction, both of which may be important for ovarian cancer development (67, 68). During postovulatory repair, OSE cells have the ability to undergo epithelial-mesenchymal transition (EMT) to modulate to a fibroblast-like form. This EMT might also function as a hemostatic mechanism to accommodate OSE cells that become trapped within the ovary at ovulation, which would allow them to become incorporated into the ovarian stroma as stromal fibroblasts. An inability to undergo EMT would preserve the epithelial forms within the ovarian stroma, and according to the stromal hypothesis (69), the repeated stimulation of the entrapped epithelium by stromal estrogens may result in increased proliferation and transformation. This suggests that stromal cell-epithelial cell interactions can influence ovarian tumor development (70, 71, 72). Cramer and Welch (73) further extended this concept by illustrating the nature of the proposed interplay between gonadotropins and estrogens. They suggest that it is the excessive gonadotropin secretion, which ultimately leads to increased estrogenic stimulation of the OSE, that is responsible for the increased risk of ovarian cancer.

A growing body of evidence indicates that several key reproductive hormones can influence the incidence and/or growth characteristics of ovarian cancer. Expression of these hormone receptors has been reported in OSE and ovarian cancer (Table 1). This, together with their roles in the physiology of normal and neoplastic OSE cells summarized in our recent review (74), is in line with the hormonal carcinogenesis hypothesis, suggesting that the endocrine factors that control the normal growth of target organs can also provide suitable conditions for neoplastic transformation. Unlike external risk factors such as diet and smoking, endogenous hormone levels are not easily modified; thus, it is important to understand the molecular changes induced by endocrine factors that might have a positive or negative association with neoplastic transformation in ovarian cancer. There have been two main hormonal hypotheses of ovarian tumorigenesis. One is an androgen/progesterone hypothesis stating that higher levels of androgens, which are increased in menopausal or obese women and also seen among women with PCOS, were associated with an increased risk of ovarian cancer, whereas progesterone can protect against ovarian cancer (75). The gonadotropin hypothesis has also been proposed as an underlying mechanism to ovarian cancer, in that excessive levels of gonadotropins, related to the surge occurring during ovulation and the loss of gonadal negative feedback for menopause and premature ovarian failure (73, 76, 77), may play a role in the development and progression of OEC. This theory would also explain the decreased risk of ovarian cancer associated with pregnancy and OC use, which results in reduced exposure to gonadotropins due to the steroid feedback on the pituitary.

View larger version (23K): [in this window] [in a new window]   FIG. 1. Temporal association between ovarian cancer incidence and gonadotropin levels. A, Age-specific incidence of and mortality from ovarian cancer, 1998–2002 (215 ). B, Change in circulating gonadotropin levels during human female lifetime (78 79 ).

Use of hormone replacement therapy (HRT) is another source for exogenous steroids; however, it does not seem to support a role of gonadotropin stimulation on ovarian cancer development. Based on the results from the Women’s Health Initiative, women who received estrogen plus progestin had an increased risk of developing invasive ovarian cancer compared with those assigned the placebo [hazard ratio, 1.6; 95% confidence interval (CI), 0.77–3.24] (85). Other epidemiological findings concerning HRT use and ovarian cancer risk are equivocal (15, 16, 17, 85, 86, 87). It is suggested that the risk for ovarian cancer may also vary with the type of HRT as well as with the duration of use and mode of administration and generally, long-term use of HRT is likely associated with an increased risk (15, 16, 85, 86, 87). The reason why the use of HRT, compared with OC, shows adverse or no effect on ovarian carcinogenesis is still poorly understood. Estrogen levels might explain this discrepancy because the mitogenic effect of estrogen has been well demonstrated in OSE and ovarian cancer (88, 89). In this regard, OC has been shown to decrease endogenous estrogen release, possibly by lowering of basal LH and FSH levels (75). It is also noteworthy that HRT is commonly prescribed for menopausal women who are insensitive to negative feedback regulation of gonadotropin secretion by steroids (90).

The ovarian cancer risk associated with ovulation induction treatment used for infertile women at in vitro fertilization processes has been considered direct evidence for the gonadotropin theory because the ovary is directly exposed to the superphysiological levels of gonadotropins for multiple follicular developments during the controlled ovarian hyperstimulation. Numerous researchers in various population pools have studied whether the superovulation with high gonadotropins is an independent risk factor for ovarian cancer. Two early studies, which prompted discussion of this issue, have suggested strong association between ovulation induction and ovarian cancer incidence. A case-control study by Whittemore et al. (17) was reported in 1992. They collected data from 2197 patients with ovarian cancer and 8893 controls in 12 U.S. case-control studies conducted from 1956 to 1986. In infertile women who had used fertility drugs, a 2.7-fold increased risk of ovarian cancer was observed; however, information on history of infertility and OC use was not provided. In 1994, Rossing et al. (18) reported the risk of ovarian tumors in a cohort of 3837 women tested for infertility between 1974 and 1985 in Seattle with 11 developed malignancies. The risk of invasive ovarian cancer development compared with that in the general population was 2.5 overall (95% CI, 1.3 to 4.5), 1.5 (95% CI, 0.4 to 3.7) in invasive ovarian cancer, and 3.3 (95% CI, 1.1–7.8) in borderline tumors. Women who used clomiphene citrate had a relative risk 2.3 times (95% CI, 0.5 to 11.4) greater than that of infertile women with no use. The risk was most prominent in women with long-term use of clomiphene citrate (12 or more cycles with a relative risk of 11.1% (95% CI, 1.5–82.3). Although this study was relatively well controlled for confounding factors such as OC use, infertility history, and type of fertility drug, it has been criticized for the small number of tumors and no discrimination between epithelial and nonepithelial tumors. Since then, most studies on this issue have observed either a weak association or no association between the infertility treatment and ovarian cancer risk (14, 19, 84, 91, 92, 93, 94, 95, 96, 97). The principal findings in these reports are well summarized in several recent reviews (98, 99, 100). Discrepancies among the findings are seemingly caused by differences in review methods. For example, studies that have limited or no information of the specific types of fertility drugs used failed to show an association between ovulation induction and ovarian cancer incidence (94, 95, 96). In contrast, other studies in which such information was available have shown a mild increase in ovarian cancer incidence with the use of human menopausal gonadotropin (97, 101). In general, epidemiological studies on fertility drug use and risk of ovarian cancer are hampered by problems, such as small study size, short follow-up time, and low prevalence of infertility and fertility drug use. In addition, most of the cohort studies have been terminated before the mean age of ovarian cancer incidence. Thus, the involvement of infertility treatment with ovarian cancer incidence is likely to be underestimated. Although the currently available findings are inconclusive, they are generally reassuring and support the need for well-designed studies including a larger population study, longer follow-up time, and a consideration of histological types and related factors such as OC use.

When investigating the pathogenesis of ovarian cancer, the gonadotropin theory cannot reconcile all the epidemiological observations. For example, the observations of the strong protective effect from a twin pregnancy or the nonprotective effect of HRT, which reduce to some extent the gonadotropin levels of menopausal women, are unlikely to be consistent with the theory. This lack of reconciliation is not unique to this theory alone, and this trait is shared by other hypotheses put forth by other investigators. Again, further research is required.

B. Animal models
Several animal studies initially drew attention to the possible involvement of gonadotropins in ovarian tumorigenesis. In 1944, Biskind and Biskind (76) reported a high incidence of ovarian tumors in rats whose ovaries were autotransplanted to the spleen. However, they failed to observe the formation of the ovarian tumors when one ovary was left intact or when the ovary was autotransplanted in previously hypophysectomized animals (102). This tumorigenesis has been attributed to elevated pituitary gonadotropins due to the deactivation of estrogen in the liver and the consequent depletion of negative feedback of estrogen on the pituitary. Since then, the development of ovarian tumors has been reported in several transgenic or knockout animal models that exhibit hypergonadotropism with high levels of circulating FSH and LH similar to the postmenopausal state in women (103, 104, 105, 106, 107). For instance, mice transgenic for the mouse inhibin promoter/Simian virus 40 (SV40) Tag fusion gene developed ovarian tumors (107). However, it should be pointed out that this animal model and as well as others, including Biskind’s model, developed nonepithelial ovarian tumors arising from stromal cells or granulosa cells. These cells were considered to have little relevance to explain the tumorigenic mechanism of the OEC. On the other hand, more recent animal studies that have focused on OSE’s proliferation or the factors involved in this process (108, 109, 110, 111) have demonstrated that administration of gonadotropins for ovulation induction significantly stimulates proliferation in the OSE. This lends support to the gonadotropin hypothesis for OEC.

One study by Davies et al. (109) monitored the proliferative activity of the OSE cells during the lifetime of the mice. The OSE cells were scarcely proliferative in adult life when compared with the prenatal period. The OSE cells of nonpregnant, pregnant, and lactating mice showed little proliferative activity, but they significantly proliferated after the administration of pregnant mare serum gonadotropin or pure recombinant gonadotropins. These data suggest that gonadotropins may play a role in the proliferation of the OSE as well as their classical role in ovarian folliculogenesis (109). Similar patterns of increased proliferation were observed in rat and rabbit OSE after administration of gonadotropins. With regard to the site and duration of proliferation, it has been demonstrated that the increased proliferation of the OSE cells occurs adjacent to the ovulatory site and the corpus luteum, and then it persists throughout most of the postovulatory period. In some studies, proliferation of the OSE cells was also detectable in nonovulatory sites after ovulation (108, 110, 111). Stewart et al. (108) further examined the effect of rupture, estrogen, and superovulation with gonadotropins on the OSE cells in two groups of rats, with and without surgically induced injury to the ovary. Here, the administration of pregnant mare serum gonadotropin and hCG led to a more than 10-fold increase in proliferation of rat OSE cells, and the effect persisted up to 40 h. In contrast, surgical injury mimicking the rupture of ovulation induced just a 5-fold increase in proliferation, and the effect was relatively transient. It is noteworthy that surgery failed to alter the response of the OSE to the gonadotropin treatment, whereas it doubled the effect of estradiol alone on OSE proliferation; thus, estrogen, but not gonadotropins, may be involved in the regulation of the wound-healing process of the OSE. Based on the results, the author postulated that hormones related to infertility treatments and HRT as well as injury- or ovulation-induced rupture of the OSE significantly stimulated proliferation of OSE cells. Consequently, this could contribute to ovarian tumorigenesis via proliferation-stimulated DNA mutations and/or a rapid selection of OSE cells with accumulated mutations (108). Experimental evidence to support the susceptibility of OSE cells to mutagenic events during mitosis is provided by studies showing that rat and mouse OSE cells, which have been repeatedly subcultured in vitro, elicits malignant transformation and the ability to form tumors in nude mice (112, 113).

One important finding published by Celik et al. (114) is that gonadotropins may associate with dysplastic morphological transformation of the OSE. Histopathological examinations in three groups of rats were performed, including one, three, and six cycles of ovulation induction groups at the 12th month after treatment ended. Malignant ovarian lesion did not develop in any of the three groups after ovulation induction; there was, however, epithelial dysplasia such as inclusion cysts, tufts, and epithelial stratification when the number of induction cycles increased. Because inclusion cysts and tufts are sites prone to develop ovarian cancer, these data seem to support the possibility that gonadotropin-induced superovulation and proliferation of OSE stimulate ovarian cancer development by increasing epithelial dysplasia in the ovary (114). Direct evidence for gonadotropins’ contribution to the initiation of experimental OEC has yet to be established. One problem here is that in contrast to humans, OSE-derived carcinomas are essentially nonexistent in rodents (35). In fact, the structure, physiology, and differentiation differ between human and rodent OSE (115, 116, 117). Thus, specially designed studies using the human surface OSE and/or inclusion cyst are necessary to explore the direct mechanism for the contribution of gonadotropins to ovarian epithelial tumorigenesis.

Most research has focused on the role of gonadotropins in the initial transformation of normal OSE to neoplastic OSE. More recently, the possible involvement of gonadotropins in tumor progression was examined in several animal models. Stewart et al. (118) developed a rat model using a carcinogen, DMBA (7, 12-dimethylbenz(a)anthracene), that closely resembled the histopathology, pattern of metastasis, and mutations of Tp53 and Ki-Ras in human OEC. Interestingly, the addition of gonadotropins after treatment with DMBA considerably increased lesion severity in this animal model. This suggested that gonadotropin stimulation may have played a contributing role in the neoplastic progression of the ovarian lesions, presumably due to the increased rate of OSE cell proliferation and their effects on the underlying stroma (118). Elevated levels of gonadotropins are also related to increased angiogenesis of ovarian cancer, probably through the regulation of vascular endothelial growth factor (VEGF). For example, ovariectomy-induced or directly administrated gonadotropins stimulated the progression of human epithelial ovarian tumors in mouse models. Magnetic resonance imaging data showed increased neovascularization of human ovarian carcinoma spheroids in ovariectomized mice, and treatment with gonadotropins up-regulated VEGF in vitro and in vivo (119). As for the mechanism of gonadotropic stimulation, it was suggested that the excessive levels of gonadotropins acts in the stroma compartment, rather than in OSE cells, as a stimulatory factor for steroidogenesis. Consequently, the steroidogenic stromal cells secrete increased levels of estrogen, which may play a mitogenic and/or carcinogenic role in the OSE cells in a paracrine manner.

Recently, data have been rapidly accumulating to demonstrate that gonadotropin receptors, FSH receptor (FSHR) and LH receptor (LHR), are expressed in the OSE as well as their classical expression sites such as granulosa and theca cells. Furthermore, when FSH and LH bind to their respective receptors, they activate various key signaling transduction pathways, resulting in a number of biological effects. These findings brought the gonadotropin theory into a new era, where the direct effect of gonadotropins in the OSE cells should be considered to be a legitimate candidate to evaluate the association of gonadotropins with ovarian tumorigenesis, as well as their indirect effects on other ovarian cells such as granulosa and theca cells. Furthermore, expression of gonadotropin receptors in ovarian cancer cells strongly suggests a potential role of gonadotropins in various aspects of ovarian cancer progression, including metastasis and chemoresistance.

C. Gonadotropin levels in patients with OEC
Several groups have studied an association of prediagnostic serum gonadotropin levels with the risk for OEC. For example, no association between serum FSH and ovarian cancer risk (120, 121) or even reverse correlation has been observed (122, 123). Similarly, data on circulating LH levels suggested that neither wild-type LH level, nor its variant containing two missense point mutations in its ß-subunit, contributes to the ovarian cancer risk (121, 124). The free ß-subunit of hCG possibly produced from the tumor is generally increased in the serum of women with ovarian cancer, in contrast to the pituitary gonadotropins (125, 126, 127). Its prognostic value has also been evaluated (128). A recent study that demonstrated the hCG-ß gene expression in ovarian cancer tissues, in contrast to the lack of its expression in noncancerous tissues, proposed the possibility that the high level of circulating hCG-ß is directly produced from ovarian cancer tissue (129). However, it is still unknown whether hCG-ß plays a physiopathological role in OEC. Interestingly, serum LH levels are associated with BRCA1 mutation status. LH levels in the follicular phase among young healthy BRCA1 mutation carriers was drastically elevated compared with noncarriers from BRCA1 families, suggesting that high levels of LH may be a part of the BRCA1 phenotype (130). In contrast, no significant difference among serum FSH levels in noncarriers, BRCA1 mutation carriers, and women from non-BRCA1/2 families was found.

The observations of serum levels of gonadotropins in women with ovarian cancer are inconsistent and in some cases appear to be contradictory to the gonadotropin hypothesis of ovarian epithelial carcinogenesis. In contrast, gonadotropin levels in ovarian cyst and peritoneal fluid appear to be associated with ovarian cancer incidence. For instance, Kramer et al. (121) found high levels of gonadotropin in cysts of serous ovarian cancer and low or absent gonadotropin levels in benign ovarian tumors. There was no significant difference in the serum FSH and LH concentrations between patients with malignant tumors and nonneoplastic cysts. LH levels in peritoneal fluid and ovarian cyst fluid from tumor aspirates was considerably higher in patients with ovarian cancer or borderline ovarian tumor than in patients with benign cysts or tumors (131, 132). The concentrations of both gonadotropins in ovarian cancer fluid were greater than in fluid from borderline tumors, benign tumors, and functional cysts of the ovary, and the serum/tumor fluid ratio was lowest in ovarian cancer (133). The observation of high levels of FSH and LH in cyst fluid of malignant ovarian tumors is consistent with the gonadotropin theory. This information suggests that FSH and LH might play a role in ovarian cancer development; however, further larger-scale experiments are necessary to confirm the relationship of the high levels of ovarian and peritoneal gonadotropins to the risk for ovarian cancer.

D. Expression of gonadotropin receptors in OSE and OEC cells
Gonadotropin receptors are G protein-coupled receptors with seven- transmembrane domains. In fact, they contain a large extracellular domain that is necessary for binding of their heterodimeric ligands, a transmembrane domain including three extracellular and intracellular loops, and a cytoplasmic domain binding to G protein. The FSHR is expressed by granulosa cells, whereas LHR is expressed by theca cells in early developing follicles and by both theca and granulosa cells during the later stages of follicular development. In addition to their primary target site, both FSHR and LHR have been found to be expressed in normal OSE cells and ovarian tumors (134, 135, 136, 137, 138, 139, 140, 141) (Table 2) with 80% of cystadenomas, 71% of borderline tumors, and 40% of epithelial ovarian carcinomas being LHR/hCGR positive. The patients with LHR-positive cancer had a better prognosis compared with those without LHR; yet there was no significant correlation between the receptor expression and the clinical stage of the disease (138). Additionally, Lu et al. (140) examined the LHR expression in tumor epithelium and tumor stroma separately. The positivity of LHR declined from precursor lesions, to benign and borderline tumors, to invasive ovarian cancer in both tumor epithelium and stroma. This information suggests a role for LH in early tumorigenesis via direct stimulation of the epithelium and/or indirect activation of stromal cells (140). Zheng et al. demonstrated the mRNA expression of FSHR in 100% of epithelial inclusions, 100% of cystadenomas, 94% of borderline tumors, and 60% of the carcinomas, and, although the result was not statistically significant, negative correlation between the positivity of FSHR and carcinoma grade was observed. This suggests that FSH may be more important in early tumorigenesis (134). Recent studies have suggested a relationship between the expression of gonadotropin receptors and ovarian cancer development (90, 140, 142). Indeed, semiquantitative RT-PCR data demonstrated that the relative mRNA levels of FSHR in ovarian cancer cells were higher than those in primary cultures of human OSE cells or in immortalized cell lines, whereas an opposite expression pattern was observed for LHR mRNA (90). These data are consistent with this recent observation that used quantitative real-time PCR. FSHR mRNA was significantly enhanced in the following order: normal OSE, benign tumors, low malignant potential (LMP) tumors, and invasive ovarian cancer (143). Furthermore, FSHR levels increased from presumed precursor lesions [ovarian epithelial inclusions (OEIs)], to benign ovarian epithelial tumor (OET), and to borderline OETs, whereas its levels decreased from borderline OETs to ovarian carcinomas (142). Together, these observations suggest that high levels of FSHR in the ovarian epithelium may play a role in tumorigenesis of ovarian cancer, especially early in the process. To investigate the role of FSHR in ovarian cancer development, we overexpressed the receptor in SV40 Tag immortalized OSE (IOSE) cells, which are preneoplastic and nontumorigenic. It should be noted that overexpression of FSHR resulted in activation of ERK1/2 MAPK and an increased expression of potential oncogenes including epidermal growth factor receptor (EGFR), c-myc, and HER-2/neu, in IOSE cells. In addition, the overexpression of FSHR accelerated cell proliferation in these cells. These results may support a pivotal role of FSHR in ovarian cancer development in terms of neoplastic conversion and growth potential (144).

	IV. Action of Gonadotropins in OSE and OEC Cells

Top Abstract I. Introduction II. Biology of Ovarian... III. Gonadotropin Theory IV. Action of Gonadotropins... V. Clinical Applications VI. Conclusion and Future... References

 
Gonadotropins may be involved in the pathogenesis and progression of ovarian cancer. They modulate gene expression that leads to changes in cell growth, apoptosis, and/or metastasis of OSE and ovarian cancer (Table 3).

A number of findings from gene expression profiling in gonadotropin-stimulated granulosa cells have suggested a possible involvement of the indirect effect of gonadotropins on granulosa cells. Gene transcripts for growth factors such as epiregulin and amphiregulin, whose binding to EGFR and/or ERB4 stimulates oncogenic/mitogenic signaling pathways, were markedly elevated in human granulosa cells after LH and FSH treatment along with the predicted amplification of steroidogenesis-related genes, such as StAR, cytochrome P450scc, and aromatase, in several cancers including ovarian cancer (158). These data are consistent with a previous finding for up-regulation of the epiregulin in granulosa layer after the administration of hCG to the rat (159). This increase in growth factors by gonadotropins may be associated with an enhanced risk not only for GCT but also for OEC due to the excessive exposure of trapped OSE to the growth factors secreted from granulosa cells.

This speculation for the role of gonadotropins in the growth factor milieu of the ovary is further supported by the findings in OSE treated with FSH or LH/hCG. In bovine OSE cells, gonadotropins increase the expression of growth factors such as keratinocyte growth factor (KGF), hepatocyte growth factor (HGF), and kit ligand, which possibly act as autocrine and/or paracrine mitogenic factors (136). Similarly, both hormones increased mRNA expression of EGFR in the bovine OSE cells, whereas hCG augmented the expression of TGF, a ligand for EGFR; yet, this was not found with FSH. Collectively, these data suggest the possible association of gonadotropins with a growth factor-receptor tyrosine kinase system in ovarian cells including the granulosa and the OSE cells, resulting in a more proliferative microenvironment for these cells (160).

B. Proliferation
FSH and LH/hCG treatment appears to regulate the growth of normal OSE, IOSE, and some ovarian cancer cells in vitro. Although administration of gonadotropins certainly stimulates proliferation of the OSE cells in most animal models (108, 109, 110, 111), the reports on the association of gonadotropins with the proliferation of OSE and ovarian cancer cells have been inconclusive. The following collection of published studies illustrates this point effectively. FSH possibly increases proliferation in the OSE and cancer cells (90, 134, 136, 141, 143, 161, 162, 163, 164, 165), yet in other studies, no association (166) and even reduced proliferation have been observed (167, 168). Some studies have reported the stimulatory effect of LH/hCG on cell growth (90, 136, 161, 163, 164, 165, 169, 170, 171, 172, 173). And again in other studies, its inhibitory effect was noticed (134, 174) and no association (166, 167) was observed. These studies were performed with highly purified or recombinant gonadotropins, indicating negligible contamination. Thus, the reason for the discrepancy in results is not known, but it may be that variations in hormone concentration or the culture density used in different studies could be affecting the outcomes (169, 170, 175). It is also possible that variations in the expression of the gonadotropin receptors or their downstream signaling molecules between cultures of OSE derived from different women may explain an inconsistent response to gonadotropins (165).

The mechanism by which gonadotropins regulate the growth of OSE and ovarian cancer cells has been controversial. A few studies suggested that there may be a relationship between gonadotropins and other hormones that have been known to be mitogenic in ovarian cancer. For instance, Kraemer et al. (163) found that OVCAR-3 has steroidogenic activity and produces estrogen responding to hCG and FSH. Because of the mitogenic effect of estradiol in ovarian cancer cells, the gonadotropin-stimulated secretion of estrogen led to growth stimulation in OVCAR-3 cells. This role of gonadotropins in steroid metabolism in OEC supports a previous finding by Wimalasena et al. (176) that about 30% of primary cystadenocarcinoma cultures respond with increased estradiol secretion to hCG and FSH. One report by Zheng et al. (177) indicated the involvement of unopposed production of activin A, which stimulates the proliferation, in an increased proliferation by FSH in ovarian cancer cells. Moreover, recent studies have suggested interactions between gonadotropins and growth factors and/or cytokines. Indeed, combined treatments of hCG with estradiol may regulate the growth response of OEC cells through a mechanism involving IGF-I (173). This finding is further supported by a recent report proposing the possible association of IGF-I and intergrin ß1 with anchorage-dependent and -independent growth of OSE cells by LH (170). In addition, FSH and hCG stimulated steady-state mRNA levels of KGF, HGF, and kit ligand in bovine OSE cells (136). Moreover, FSH-, LH-, and estrogen-stimulated IOSE cell proliferation involves the IL-6/signal transducer and activator of transcription-3 (STAT3) signaling pathway (90, 178).

With regard to the signaling pathways, it is generally accepted that the effects of gonadotropins on classical target cells such as granulosa and Leydig cells are mediated by the protein kinase A (PKA) pathway, such that activation of adenylyl cyclase by the stimulatory G protein, Gs, is followed by a rapid increase in cAMP and a subsequent activation of PKA (179). Some studies have proposed that the PKA pathway is also involved in gonadotropin-induced proliferation of OSE and ovarian cancer cells. For example, a specific PKA inhibitor, H89, completely abolished gonadotropin-stimulated cell growth via the IL-6/STAT3 pathway in human OSE and ovarian cancer (90, 178). Interestingly, growing evidence shows that FSHR and LHR can activate a number of additional cellular signaling pathways: protein kinase C (PKC), phosphatidylinositol 3-kinase (PI3K), and MAPK in granulosa, OSE, and ovarian cancer cells (180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190). Treatment of OEC cells with FSH significantly increased the levels of PKC mRNA and protein, suggesting that the stimulation of PKC transcription is involved in FSH-induced cell proliferation (162).

Our findings have also demonstrated that after treatment with FSH, phosphorylation of ERK1/2 and cell growth were significantly increased in preneoplastic IOSE-29 and neoplastic IOSE-29EC cells (191). FSH-induced activation of ERK1/2 and proliferation were completely abolished in the presence of PD98059, suggesting that the growth-stimulatory effect of FSH is mediated by ERK1/2. In addition, treatment with FSH significantly phosphorylated a transcription factor, Elk-1, a recognized downstream target of ERK1/2. The fact that FSH did not stimulate basal cAMP levels in OSE cells, but was observed in human granulosa cells, is a noteworthy observation (141).

More recently, we reported that gonadotropins up-regulate EGFR levels through activation of ERK1/2 and PI3K in human IOSE cells (192) (Fig. 2). Treatment of IOSE-80PC cells with FSH and LH resulted in a significant increase in EGFR mRNA at 24 h and EGFR protein at 48 h, whereas only a mild increase was observed in OVCAR-3 cells. In addition, IOSE-80PC cells treated with gonadotropins and EGF exhibited an additive stimulation of mitogenesis. FSH and LH significantly increased the activities of various kinases at 5–10 min. Pretreatments with LY294002 (an inhibitor of PI3K) or PD98059 (an inhibitor of MEK1) partially blocked gonadotropin-induced up-regulation of EGFR mRNA in IOSE-80PC cells. Our results suggest that FSH and LH use alternate mechanisms to increase EGFR mRNA, such that the former increases EGFR gene transcription, whereas the latter enhances EGFR mRNA stability. Taken together, these results suggest that FSH- and LH-induced activation of the ERK1/2 and PI3K/protein kinase B (Akt) pathways may affect cell growth by means of a direct mitogenic effect or by interaction with a growth factor system(s), such as EGFR, in preneoplastic OSE cells.

View larger version (14K): [in this window] [in a new window]   FIG. 2. Effect of gonadotropins on the expression EGFR and cell growth. The expression level of EGFR mRNA (A) and protein (B) was examined in IOSE-80PC (80PC) and OVCAR3 cells after treatment with FSH (10–7 and 10–6 g/ml) and LH (10–7 and 10–6 g/ml) for 24 h or 48 h, and RT-PCR and Western blot were performed. Line 1, Control; line 2, FSH 10–7 g/ml; line 3, FSH 10–6 g/ml; line 4, LH 10–7 g/ml; line 5, LH 10–6 g/ml. Data are shown as the means of three individual blots, and are presented as the mean ± SD. a, P < 0.05 vs. nontreated cells. The cells were treated with FSH or LH (10–7 g/ml) and EGF (10 nM) for 6 d, and a [3H]thymidine incorporation assay was performed in IOSE-80PC cells (C). Data are shown as the means of three individual experiments performed in triplicate and are presented as the mean ± SD. a, P < 0.05 vs. untreated control; b, P < 0.05 vs. EGF-only treated group. [Reproduced with permission from Choi et al.: Endocr Relat Cancer 12:407–421, 2005 (192 ).]

C. Apoptosis
The overall 5-yr survival rate for advanced ovarian cancer patients is low (20–30%) due to chemoresistance to conventional cytotoxic drugs such as cisplatin in the primary or recurrent tumors that results in treatment failure (200, 201). Compared with the effects of gonadotropins on proliferation of OSE and OEC cells, little is known about whether gonadotropins play a role in chemosensitivity of ovarian cancer. During ovarian folliculogenesis, gonadotropins—especially FSH—changed the expression of antiapoptotic proteins such as Bax (202) and XIAP in granulosa cells and inhibited apoptosis (203). In ovarian cancer, limited data that have examined the link between gonadotropins and regulation of apoptosis are available. In OVCAR-3 cells bearing LHR, LH remarkably inhibited cisplatin-induced apoptosis by increasing the expression of IGF, but not Bcl-2 family proteins such as Bcl-2 and Bax (172). The TNF receptor superfamily member 6 (Fas) system is well known to mediate the cisplatin cytotoxicity. LH interfered with the Fas-induced apoptosis in HEY and CaOV-3 cells (204). Similarly, a study found that pretreatment of OVCAR-3 cells with FSH significantly reduced cisplatin-induced apoptosis and cell cycle arrest using various methods such as MTT, TUNEL assay, and flow cytometry. Furthermore, this inhibitory effect is mediated by overexpression of an inhibitor of apoptosis protein family survivin and down-regulation of caspase activity (205, 206). These data indicate that gonadotropins may be involved in chemoresistance, which is a main hurdle for ovarian cancer management. Accordingly, some reports revealed the antiapoptotic effect of gonadotropins in OSE cells (165, 172).

D. Invasion and angiogenesis
The adhesion and angiogenesis of ovarian cancer play a crucial role in peritoneal metastatic dissemination and nutrition supply, resulting in the progression of ovarian cancer via invasion and metastasis. Gonadotropins enhance tumor angiogenesis and adhesion in ovarian cancer cells (119, 207, 208, 209). Schiffenbauer et al. (119) found that human OEC progressed faster with increased neovascularization in ovariectomized mice as a result of elevated FSH and LH levels, which promoted the expression of VEGF in a dose-dependent manner in vitro. Neovascularization was significantly increased both in vitro and in vivo by hCG (207). Gonadotropins up-regulated VEGF expression in both malignant and borderline tumor; however, the effect of gonadotropins was significantly stronger in malignant tumor than in borderline tumor (209). In addition to angiogenesis and vascular remodeling, treatment with gonadotropins increased integrin v and CD44, the cell surface hyaluronan receptor, resulting in enhanced adhesion of the cancer cells to culture plates coated with hyaluronan, fibronectin, as well as a thrombin-derived RGD containing peptide (208). One significant finding we discovered was that treatment with FSH or LH significantly increased the invasion of ovarian cancer cells, including BG-1, CaOV-3, and SKOV-3 cells (210) (Fig. 3). Treatment of SKOV-3 cells with FSH or LH enhanced the net balance of metalloproteinase (MMP)-2 and -9/ tissue inhibitor of metalloproteinase (TIMP)-1 and -2, resulting in enhanced proteolytic activities. In addition to the above finding, we demonstrated that gonadotropins induced an increase in SKOV-3 invasiveness via the activation of PKA and PI3K signaling pathways. No association was observed between gonadotropins and urokinase-type plasminogen activator (210, 211).

View larger version (20K): [in this window] [in a new window]   FIG. 3. Effect of FSH and LH on invasion and MMP production in ovarian cancer cells. OVCAR-3, CaOV-3, BG-1, and SKOV-3 cells were seeded in Matrigel-coated invasion chambers in the presence or absence of FSH or LH (10, 100, and 1000 ng/ml) (A). Con, Control; F10, FSH 10 ng/ml; FSH100, FSH 100 ng/ml; FSH1000, FSH 1000 ng/ml; LH10, LH 10 ng/ml; LH100, LH 100 ng/ml; and LH1000, LH 1000 ng/ml. After incubation for 2 d, filters were stained and invading cells were quantified using an inverted microscope. After 20-min pretreatments with 10 µM LY294002 (PI3K inhibitor), 10 µM PD98059 (MAPK inhibitor), 10 µM GF109203 (PKA inhibitor), 20 µM SB203580 (p38 inhibitor), or 10 µM H89 (PKA inhibitor), the cells were treated with FSH or LH (100 ng/ml), and the invasion assay (B) or Western blot (C) was performed. Data are shown as the mean ± SD of three individual experiments. a, P < 0.05 vs. nontreated cells. [Reproduced with permission from Choi et al.: Cancer Res 66:3912–3920, 2006(210 ).]

	V. Clinical Applications

Top Abstract I. Introduction II. Biology of Ovarian... III. Gonadotropin Theory IV. Action of Gonadotropins... V. Clinical Applications VI. Conclusion and Future... References

B. Hormone therapy
Surgical removal of most, if not all of the cancer, followed by anticancer chemotherapy is the routine treatment for ovarian carcinoma. However, various hormone therapies, such as antiestrogens, progestins, GnRH analogs, and antiandrogens have been tested in recurrent and/or chemoresistant ovarian cancer patients. GnRH analogs including both agonist (triptorelin and leuprolide) and antagonist agents (cetrorelix and flutamide) reduce gonadotropin secretion from the pituitary through eventual desensitization of the pituitary receptors. Several clinical studies upon the gonadotropin theory were carried out using these hormonal analogs. Initially, a number of phase I and phase II clinical trials suggested that GnRH analogs may result in relevant response and/or disease stabilization in 10–30% of patients with refractory ovarian cancer (217). Despite these encouraging results, the benefit of using GnRH analogs as a second-line therapy of advanced ovarian cancer is debatable. In several recent studies, the GnRH agonists, such as leuprolide and triptorelin, were used as a second-line therapy (218). Generally some, but not all, agonists showed modest efficacy in patients with platinum-refractory ovarian cancer (219, 220, 221). The GnRH antagonist cetrorelix was also tested in a phase II study. Of 17 patients who received GnRH antagonist cetrorelix 10 mg sc daily, three had partial remissions lasting 9, 16, and 17 wk with minor toxicity, but incurred potential anaphylactic reactions (222). This is likely consistent with a observation that cetrorelix, alone or in combination with the bombesin/gastrin-releasing peptide antagonist, effectively inhibited the growth of ES-2 cells engrafted nude mice (222, 223).

The combination therapy of another GnRH agonist goserelin with antiestrogenic tamoxifen or conventional platinum regimens has shown promise in the treatment of the malignancy. Patients with recurrent ovarian cancer that were treated with oral tamoxifen 20 mg twice daily and sc goserelin 3.6 mg once a month until disease showed progression. About 50% of patients exhibited an "endocrine response," including patients with complete response (3.8%), partial responses (7.7%), and stable disease (38.5%) (224). In a study that tested the combination effect of chemotherapy, radiotherapy, and goserelin, the chemotherapy was effective only with goserelin treatment or radiotherapy. In the goserelin treatment group, the 5-yr survival rate rose 54% in contrast to only 19% in the nontreatment group. Of the goserelin treatment group, patients surviving at least 5 yr or in complete remission at the time of this study showed significantly lower FSH levels in serum (225). In addition to lowering the circulating levels of gonadotropins, the antiproliferative and/or apoptosis-inducing effect of GnRH analogs via their receptor in the ovarian cancer cells has been implicated as their supplementary mechanism of action (224). In fact, GnRHR is expressed in about 80% of ovarian cancer and its ligands. Both GnRH I and GnRH II have been shown to inhibit cell growth (226, 227, 228, 229, 230). The conclusion drawn from these studies is that hormonal therapies including the GnRH analogs may be beneficial because of their relatively lower toxicity, fewer side effects, and higher tolerability.

C. Drug development
A number of researchers have attempted to increase the specificity of conventional cytotoxic drugs based on the common expression of gonadotropin receptors in ovarian cancer cells. Despite a general prolonged survival rate by conventional chemotherapies that contain platinum, taxanes, and anthracyclines for ovarian cancer, there has been limited use of chemotherapy regimens due to significant side effects and a high recurrence rate. Cytostatics conjugated with hCG have significantly increased the toxicity in LHR-expressing breast (231) and prostate cancer cells (232, 233). Treatment with hCG-conjugated doxorubicin for 2 h induced more than an 8-fold increase in cytotoxicity compared with unconjugated doxorubicin in ovarian cancer. This effect showed prolonged antiproliferative action up to 168 h rather than an acute cytotoxic action (234). The conjugate-induced cytotoxicity in ovarian cancer cells was likely dependent on LHR expression levels (235). A similar study on lytic peptides conjugated to hCG-ß has shown that the conjugates selectively destroy OVCAR-3 cells in vitro and OVCAR-3 cells engrafted in nude mice models in vivo (236). In a group of animals treated by hecate-hCG-ß, tumor volume expressed as a percentage of increase was 199 ± 18.57% when compared with control animals (263.0 ± 21.72%). The expression of LHR was increased when estradiol was present (236), resulting in a positive correlation between steroids in the culture medium and sensitivity of the OVCAR-3 cells to the hecate-hCG-ß. Together, these findings suggest that cytotoxic drugs conjugated with gonadotropins may be used for treating gonadotropin receptors-bearing OEC.

	VI. Conclusion and Future Directions

Top Abstract I. Introduction II. Biology of Ovarian... III. Gonadotropin Theory IV. Action of Gonadotropins... V. Clinical Applications VI. Conclusion and Future... References

 
The OEC encompasses a diverse and biologically complex group of malignant neoplasms with a dismal clinical prognosis. There is an urgent need for a better understanding of its pathogenesis, identification of specific diagnostic/prognostic factors, and development of new preventive and/or therapeutic approaches. The epidemiological studies that have focused on the theory that excessive gonadotropins may play a role in the development of OEC are not completely conclusive (Table 4). A deeper and comprehensive analysis with a large population study that provides a longer follow-up and includes a consideration of histological types and related factors such as OC use should provide a better understanding of how gonadotropins influence cancer risk. Supporting evidence of ovarian epithelial tumorigenesis from animal models with targeted manipulation of gonadotropin secretion or action would be particularly desirable, but it has yet to be established and is an area for future research. The reported observations here on gonadotropins’ role in OEC, including proliferation, apoptosis, adhesion, invasion, and angiogenesis, not only confirm their importance in the cancer process, but also may prove to be an integral part of the translation into clinical applications to eliminate primary and metastatic ovarian cancers. Additionally, the role of gonadotropin in ovarian cancer development should be further explored in terms of its possible involvement with stromal-epithelial interaction and regulation of OSE stem cell self-renewal and differentiation. The recent cDNA microarray analyses and characterization in the molecular mechanisms of gonadotropin signaling have indicated the effects of gonadotropins on the regulation of normal OSE and OEC cell growth, survival, and metastasis and may involve other growth factors mediated by a complex array of intracellular signaling pathways (Fig. 4). These studies provide a great deal of novel information on understudied mechanisms involved in dysregulation of gonadotropin functions. Further investigation may establish a new paradigm of therapy for targeting ovarian cancer at the molecular level. Finally, the differential expression pattern of gonadotropins and their receptors in ovarian epithelial tumors in relation to clinicopathological parameters will be important for the identification of potential diagnostic/prognostic markers and drug targets for ovarian cancer. Understanding the physiopathological role of gonadotropins in this devastating disease is an important and understudied area that could help inform clinical screening processes and improve drug therapies, thus, improving the survival rate for ovarian cancer.

View larger version (12K): [in this window] [in a new window]   FIG. 4. Diagrammatic representation of gonadotropins signaling in OSE and OEC. Gonadotropins bind to their specific receptor and activate downstream signaling pathway, including PKA, PI3K/Akt, and MAPK cascades, resulting in the regulation of cell growth, apoptosis, and metastasis in OSE and/or ovarian cancer. AC, Adenylyl cyclase; Ga, G-protein s.

	Footnotes

 
This work was supported by grants from the Canadian Institutes of Health Research (to P.C.K.L.), the Hong Kong Research Grants Council (to A.S.T.W.), and the National Basic Research Program of China (2006CB504004; to H.-F.H.). J.-H.C. is a recipient of a trainee award from the Interdisciplinary Women’s Reproductive Health research training program. P.C.K.L. is a recipient of Distinguished Scientist awards from the Michael Smith Foundation for Health Research and the Child and Family Research Institute.

There is nothing to disclose.

First Published Online April 26, 2007

Abbreviations: Akt, Protein kinase B; APPL1, adaptor protein containing PH domain, PTB domain, and leucine zipper motif; CI, confidence interval; EGF, epidermal growth factor; EGFR, EGF receptor; EMT, epithelial-mesenchymal transition; Epac, exchange protein directly activated by cAMP; Fas, TNF receptor superfamily member 6; FSHR, FSH receptor; GCT, granulosa cell tumor(s); hCG, human chorionic gonadotropin; HGF, hepatocyte growth factor; HRT, hormone replacement therapy; IOSE, immortalized OSE; KGF, keratinocyte growth factor; LHR, LH receptor; LMP, low malignant potential; MMP, metalloproteinase; OC, oral contraceptive; OEC, ovarian epithelial cancer; OEI, ovarian epithelial inclusion; OSE, ovarian surface epithelium; PCOS, polycystic ovary syndrome; PI3K, phosphoinositol 3 kinase; PKA, protein kinase A; PKC, protein kinase C; SNP, single nucleotide polymorphism; STAT-3, signal transducers and activators of transcription-3; SV40, Simian virus 40; TIMP, tissue inhibitor of metalloproteinase; VEGF, vascular endothelial growth factor.

	References

Top Abstract I. Introduction II. Biology of Ovarian... III. Gonadotropin Theory IV. Action of Gonadotropins... V. Clinical Applications VI. Conclusion and Future... References

 

1. Rao MC, Midgley Jr AR, Richards JS 1978 Hormonal regulation of ovarian cellular proliferation. Cell 14:71–78[CrossRef][Medline]
2. Richards JS, Farookhi R 1978 Gonadotrophins and ovarian-follicular growth. Clin Obstet Gynaecol 5:363–373[Medline]
3. Gadducci A, Cosio S, Gargini A, Genazzani AR 2004 Sex-steroid hormones, gonadotropin and ovarian carcinogenesis: a review of epidemiological and experimental data. Gynecol Endocrinol 19:216–228[CrossRef][Medline]
4. Heintz AP, Odicino F, Maisonneuve P, Beller U, Benedet JL, Creasman WT, Ngan HY, Sideri M, Pecorelli S 2001 Carcinoma of the ovary. J Epidemiol Biostat 6:107–138[Medline]
5. Tingulstad S, Skjeldestad FE, Halvorsen TB, Hagen B 2003 Survival and prognostic factors in patients with ovarian cancer. Obstet Gynecol 101:885–891[CrossRef][Medline]
6. Modugno F, Ness RB, Cottreau CM 2002 Cigarette smoking and the risk of mucinous and nonmucinous epithelial ovarian cancer. Epidemiology 13:467–471[CrossRef][Medline]
7. Green A, Purdie D, Bain C, Siskind V, Webb PM 2001 Cigarette smoking and risk of epithelial ovarian cancer (Australia). Cancer Causes Control 12:713–719[CrossRef][Medline]
8. Marchbanks PA, Wilson H, Bastos E, Cramer DW, Schildkraut JM, Peterson HB 2000 Cigarette smoking and epithelial ovarian cancer by histologic type. Obstet Gynecol 95:255–260[CrossRef][Medline]
9. Chang S, Risch HA 1997 Perineal talc exposure and risk of ovarian carcinoma. Cancer 79:2396–2401[CrossRef][Medline]
10. Harlow BL, Cramer DW, Bell DA, Welch WR 1992 Perineal exposure to talc and ovarian cancer risk. Obstet Gynecol 80:19–26[Medline]
11. Ness RB, Cottreau C 1999 Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer Inst 91:1459–1467[Abstract/Free Full Text]
12. Modugno F, Ness RB, Allen GO 2003 Alcohol consumption and the risk of mucinous and nonmucinous epithelial ovarian cancer. Obstet Gynecol 102:1336–1343[CrossRef][Medline]
13. Swisher E 2003 Ovarian cancer associated with inherited mutations in BRCA1 or BRCA2. Curr Womens Health Rep 3:27–32[Medline]
14. Ness RB, Cramer DW, Goodman MT, Kjaer SK, Mallin K, Mosgaard BJ, Purdie DM, Risch HA, Vergona R, Wu AH 2002 Infertility, fertility drugs, and ovarian cancer: a pooled analysis of case-control studies. Am J Epidemiol 155:217–224[Abstract/Free Full Text]
15. Riman T, Dickman PW, Nilsson S, Correia N, Nordlinder H, Magnusson CM, Weiderpass E, Persson IR 2002 Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women. J Natl Cancer Inst 94:497–504[Abstract/Free Full Text]
16. Lacey Jr JV, Mink PJ, Lubin JH, Sherman ME, Troisi R, Hartge P, Schatzkin A, Schairer C 2002 Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA 288:334–341[Abstract/Free Full Text]
17. Whittemore AS, Harris R, Itnyre J 1992 Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol 136:1184–1203[Abstract/Free Full Text]
18. Rossing MA, Daling JR, Weiss NS, Moore DE, Self SG 1994 Ovarian tumors in a cohort of infertile women. N Engl J Med 331:771–776[Abstract/Free Full Text]
19. Anderson SM, Dimitrievich E 1996 Ovulation induction for infertility: is it safe or not? S D J Med 49:419–421[Medline]
20. Risch HA, Marrett LD, Jain M, Howe GR 1996 Differences in risk factors for epithelial ovarian cancer by histologic type. Results of a case-control study. Am J Epidemiol 144:363–372[Abstract/Free Full Text]
21. Hankinson SE, Colditz GA, Hunter DJ, Willett WC, Stampfer MJ, Rosner B, Hennekens CH, Speizer FE 1995 A prospective study of reproductive factors and risk of epithelial ovarian cancer. Cancer 76:284–290[CrossRef][Medline]
22. Modugno F, Ness RB, Allen GO, Schildkraut JM, Davis FG, Goodman MT 2004 Oral contraceptive use, reproductive history, and risk of epithelial ovarian cancer in women with and without endometriosis. Am J Obstet Gynecol 191:733–740[CrossRef][Medline]
23. Bosetti C, Negri E, Trichopoulos D, Franceschi S, Beral V, Tzonou A, Parazzini F, Greggi S, La Vecchia C 2002 Long-term effects of oral contraceptives on ovarian cancer risk. Int J Cancer 102:262–265[CrossRef][Medline]
24. Tung KH, Wilkens LR, Wu AH, McDuffie K, Nomura AM, Kolonel LN, Terada KY, Goodman MT 2005 Effect of anovulation factors on pre- and postmenopausal ovarian cancer risk: revisiting the incessant ovulation hypothesis. Am J Epidemiol 161:321–329[Abstract/Free Full Text]
25. Kurian AW, Balise RR, McGuire V, Whittemore AS 2005 Histologic types of epithelial ovarian cancer: have they different risk factors? Gynecol Oncol 96:520–530[CrossRef][Medline]
26. Ness RB, Grisso JA, Vergona R, Klapper J, Morgan M, Wheeler JE 2001 Oral contraceptives, other methods of contraception, and risk reduction for ovarian cancer. Epidemiology 12:307–312[CrossRef][Medline]
27. Parazzini F, Negri E, La Vecchia C, Luchini L, Mezzopane R 1993 Hysterectomy, oophorectomy, and subsequent ovarian cancer risk. Obstet Gynecol 81:363–366[Medline]
28. Gocze PM, Beamer WG, de Jong FH, Freeman DA 1997 Hormone synthesis and responsiveness of spontaneous granulosa cell tumors in (SWR x SWXJ-9) F1 mice. Gynecol Oncol 65:143–148[CrossRef][Medline]
29. Healy DL, Burger HG, Mamers P, Jobling T, Bangah M, Quinn M, Grant P, Day AJ, Rome R, Campbell JJ 1993 Elevated serum inhibin concentrations in postmenopausal women with ovarian tumors. N Engl J Med 329:1539–1542[Abstract/Free Full Text]
30. Fuller PJ, Verity K, Shen Y, Mamers P, Jobling T, Burger HG 1998 No evidence of a role for mutations or polymorphisms of the follicle-stimulating hormone receptor in ovarian granulosa cell tumors. J Clin Endocrinol Metab 83:274–279[Abstract/Free Full Text]
31. Chu S, Rushdi S, Zumpe ET, Mamers P, Healy DL, Jobling T, Burger HG, Fuller PJ 2002 FSH-regulated gene expression profiles in ovarian tumours and normal ovaries. Mol Hum Reprod 8:426–433[Abstract/Free Full Text]
32. Graves PE, Surwit EA, Davis JR, Stouffer RL 1985 Adenylate cyclase in human ovarian cancers: sensitivity to gonadotropins and nonhormonal activators. Am J Obstet Gynecol 153:877–882[Medline]
33. Stouffer RL, Grodin MS, Davis JR, Surwit EA 1984 Investigation of binding sites for follicle-stimulating hormone and chorionic gonadotropin in human ovarian cancers. J Clin Endocrinol Metab 59:441–446[Abstract/Free Full Text]
34. Mikola M, Kero J, Nilson JH, Keri RA, Poutanen M, Huhtaniemi I 2003 High levels of luteinizing hormone analog stimulate gonadal and adrenal tumorigenesis in mice transgenic for the mouse inhibin--subunit promoter/Simian virus 40 T-antigen fusion gene. Oncogene 22:3269–3278[CrossRef][Medline]
35. Auersperg N, Wong AS, Choi KC, Kang SK, Leung PC 2001 Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev 22:255–288[Abstract/Free Full Text]
36. Chen VW, Ruiz B, Killeen JL, Cote TR, Wu XC, Correa CN 2003 Pathology and classification of ovarian tumors. Cancer 97:2631–2642[CrossRef][Medline]
37. Nicosia SV, Johnson JH 1984 Surface morphology of ovarian mesothelium (surface epithelium) and of other pelvic and extrapelvic mesothelial sites in the rabbit. Int J Gynecol Pathol 3:249–260[Medline]
38. Herbst AL 1994 The epidemiology of ovarian carcinoma and the current status of tumor markers to detect disease. Am J Obstet Gynecol 170:1099–1105; discussion 1105–1097[Medline]
39. Auersperg N, Edelson MI, Mok SC, Johnson SW, Hamilton TC 1998 The biology of ovarian cancer. Semin Oncol 25:281–304[Medline]
40. Murdoch WJ 1994 Ovarian surface epithelium during ovulatory and anovulatory ovine estrous cycles. Anat Rec 240:322–326[CrossRef][Medline]
41. Scully RE 1995 Pathology of ovarian cancer precursors. J Cell Biochem Suppl 23:208–218[Medline]
42. Maines-Bandiera SL, Auersperg N 1997 Increased E-cadherin expression in ovarian surface epithelium: an early step in metaplasia and dysplasia? Int J Gynecol Pathol 16:250–255[Medline]
43. Blaustein A, Kaganowicz A, Wells J 1982 Tumor markers in inclusion cysts of the ovary. Cancer 49:722–726[CrossRef][Medline]
44. Mittal KR, Goswami S, Demopoulos RI 1995 Immunohistochemical profile of ovarian inclusion cysts in patients with and without ovarian carcinoma. Histochem J 27:119–122[Medline]
45. Roland IH, Yang W-L, Yang D-H, Daly MB, Ozols RF, Hamilton TC, Lynch HT, Godwin AK, Xu X-X 2003 Loss of surface and cyst epithelial basement membranes and preneoplastic morphologic changes in prophylactic oophorectomies. Cancer 98:2607–2623[CrossRef][Medline]
46. Capo-Chichi CD, Smith ER, Yang DH, Roland IH, Vanderveer L, Cohen C, Hamilton TC, Godwin AK, Xu XX 2002 Dynamic alterations of the extracellular environment of ovarian surface epithelial cells in premalignant transformation, tumorigenicity, and metastasis. Cancer 95:1802–1815[CrossRef][Medline]
47. Ozols RF, Bookman MA, Connolly DC, Daly MB, Godwin AK, Schilder RJ, Xu X, Hamilton TC 2004 Focus on epithelial ovarian cancer. Cancer Cell 5:19–24[CrossRef][Medline]
48. Li L, Xie T 2005 Stem cell niche: structure and function. Annu Rev Cell Dev Biol 21:605–631[CrossRef][Medline]
49. Bukovsky A, Svetlikova M, Caudle MR 2005 Oogenesis in cultures derived from adult human ovaries. Reprod Biol Endocrinol 3:17[CrossRef][Medline]
50. Bukovsky A, Caudle MR, Svetlikova M, Upadhyaya NB 2004 Origin of germ cells and formation of new primary follicles in adult human ovaries. Reprod Biol Endocrinol 2:20[CrossRef][Medline]
51. Reya T, Clevers H 2005 Wnt signalling in stem cells and cancer. Nature 434:843–850[CrossRef][Medline]
52. Mimeault M, Batra SK 2006 Recent advances on multiple tumorigenic cascades involved in prostatic cancer progression and targeting therapies. Carcinogenesis 27:1–22[Abstract/Free Full Text]
53. Bapat SA, Mali AM, Koppikar CB, Kurrey NK 2005 Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer Res 65:3025–3029[Abstract/Free Full Text]
54. Baik I, Devito WJ, Ballen K, Becker PS, Okulicz W, Liu Q, Delpapa E, Lagiou P, Sturgeon S, Trichopoulos D, Quesenberry PJ, Hsieh CC 2005 Association of fetal hormone levels with stem cell potential: evidence for early life roots of human cancer. Cancer Res 65:358–363[Abstract/Free Full Text]
55. Mimeault M, Bonenfant D, Batra SK 2004 New advances on the functions of epidermal growth factor receptor and ceramides in skin cell differentiation, disorders and cancers. Skin Pharmacol Physiol 17:153–166[Medline]
56. Fathalla MF 1971 Incessant ovulation–a factor in ovarian neoplasia? Lancet 2:163[CrossRef][Medline]
57. Casagrande JT, Louie EW, Pike MC, Roy S, Ross RK, Henderson BE 1979 "Incessant ovulation" and ovarian cancer. Lancet 2:170–173[CrossRef][Medline]
58. Greenlee RT, Murray T, Bolden S, Wingo PA 2000 Cancer statistics, 2000. CA Cancer J Clin 50:7–33[Abstract]
59. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE 1994 Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 343:692–695[CrossRef][Medline]
60. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, Sobol H, Teare MD, Struewing J, Arason A, Scherneck S, Peto J, Rebbeck TR, Tonin P, Neuhausen S, Barkardottir R, Eyfjord J, Lynch H, Ponder BA, Gayther SA, Birch JM, Lindblom A, Stoppa-Lyonnet D, Bignon Y, Borg A, Hamann U, Haites N, Scott RJ, Maugard CM, Vasen H, Seitz S, Cannon-Albright LA, Schofield A, Zelada-Hedman M, and the Breast Cancer Linkage Consortium 1998 Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 62:676–689[CrossRef][Medline]
61. Lambe M, Wuu J, Rossing MA, Hsieh CC 1999 Twinning and maternal risk of ovarian cancer. Lancet 353:1941[CrossRef][Medline]
62. Frost C, Coleman MP 1997 Obesity and ovarian cancer. Eur J Cancer 33:1529–1531[CrossRef][Medline]
63. Purdie DM, Bain CJ, Webb PM, Whiteman DC, Pirozzo S, Green AC 2001 Body size and ovarian cancer: case-control study and systematic review (Australia). Cancer Causes Control 12:855–863[CrossRef][Medline]
64. Mink PJ, Folsom AR, Sellers TA, Kushi LH 1996 Physical activity, waist-to-hip ratio, and other risk factors for ovarian cancer: a follow-up study of older women. Epidemiology 7:38–45[Medline]
65. Dal Maso L, Franceschi S, Negri E, Conti E, Montella M, Vaccarella S, Canzonieri V, Parazzini F, La Vecchia C 2002 Body size indices at different ages and epithelial ovarian cancer risk. Eur J Cancer 38:1769–1774[CrossRef][Medline]
66. Schildkraut JM, Schwingl PJ, Bastos E, Evanoff A, Hughes C 1996 Epithelial ovarian cancer risk among women with polycystic ovary syndrome. Obstet Gynecol 88:554–559[CrossRef][Medline]
67. Ness RB, Modugno F 2006 Endometriosis as a model for inflammation-hormone interactions in ovarian and breast cancers. Eur J Cancer 42:691–703[CrossRef][Medline]
68. Somigliana E, Vigano P, Parazzini F, Stoppelli S, Giambattista E, Vercellini P 2006 Association between endometriosis and cancer: a comprehensive review and a critical analysis of clinical and epidemiological evidence. Gynecol Oncol 101:331–341[CrossRef][Medline]
69. Cramer DW, Barbieri RL, Fraer AR, Harlow BL 2002 Determinants of early follicular phase gonadotrophin and estradiol concentrations in women of late reproductive age. Hum Reprod 17:221–227[Abstract/Free Full Text]
70. Vigne JL, Halburnt LL, Skinner MK 1994 Characterization of bovine ovarian surface epithelium and stromal cells: identification of secreted proteins. Biol Reprod 51:1213–1221[Abstract]
71. Nilsson E, Doraiswamy V, Parrott JA, Skinner MK 2001 Expression and action of transforming growth factor ß (TGFß1, TGFß2, TGFß3) in normal bovine ovarian surface epithelium and implications for human ovarian cancer. Mol Cell Endocrinol 182:145–155[CrossRef][Medline]
72. Parrott JA, Kim G, Skinner MK 2000 Expression and action of kit ligand/stem cell factor in normal human and bovine ovarian surface epithelium and ovarian cancer. Biol Reprod 62:1600–1609[Abstract/Free Full Text]
73. Cramer DW, Welch WR 1983 Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. J Natl Cancer Inst 71:717–721[Medline]
74. Leung PC, Choi JH 2007 Endocrine signaling in ovarian surface epithelium and cancer. Hum Reprod Update 13:143–162[Abstract/Free Full Text]
75. Risch H 1998 Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. JNCI Cancer Spectrum 90:1774–1786
76. Biskind MS, Biskind GR 1944 Development of tumors in the rat ovary after transplantation into the spleen. Proc Soc Exp Biol Med 55:176–179[CrossRef]
77. Vanderhyden BC 2005 Loss of ovarian function and the risk of ovarian cancer. Cell Tissue Res 322:117–124[CrossRef][Medline]
78. Chakravarti S, Collins WP, Forecast JD, Newton JR, Oram DH, Studd JW 1976 Hormonal profiles after the menopause. Br Med J 2:784–787[Abstract/Free Full Text]
79. Speroff L, Glass R, Kase N 1999 Clinical gynecologic endocrinology and infertility. Sixth ed. Baltimore: Lippincott Williams & Wilkins
80. Ries LA, Miller BA, Hankey BF, Kosary CL, Harras A, Edwards BK 1994 SEER cancer statistics review, 1973–1991: tables and graphs. Bethesda, MD: National Institutes of Health Publication
81. Weiss NS, Cook LS, Farrow DC, Rosenblatt KA 1996 Ovarian cancer. In: Schottenfeld D, Faumeni, FSJ, eds. Cancer epidemiology and prevention. New York: Oxford University Press; 1040–1057
82. McGuire V, Felberg A, Mills M, Ostrow KL, DiCioccio R, John EM, West DW, Whittemore AS 2004 Relation of contraceptive and reproductive history to ovarian cancer risk in carriers and noncarriers of BRCA1 gene mutations. Am J Epidemiol 160:613–618[Abstract/Free Full Text]
83. Purdie D, Green A, Bain C, Siskind V, Ward B, Hacker N, Quinn M, Wright G, Russell P, Susil B 1995 Reproductive and other factors and risk of epithelial ovarian cancer: an Australian case-control study. Survey of Women’s Health Study Group. Int J Cancer 62:678–684[Medline]
84. Franceschi S, La Vecchia C, Negri E, Guarneri S, Montella M, Conti E, Parazzini F 1994 Fertility drugs and risk of epithelial ovarian cancer in Italy. Hum Reprod 9:1673–1675[Abstract/Free Full Text]
85. Anderson GL, Manson J, Wallace R, Lund B, Hall D, Davis S, Shumaker S, Wang CY, Stein E, Prentice RL 2003 Implementation of the Women’s Health Initiative study design. Ann Epidemiol 13:S5–S17
86. Chiaffarino F, Pelucchi C, Parazzini F, Negri E, Franceschi S, Talamini R, Conti E, Montella M, La Vecchia C 2001 Reproductive and hormonal factors and ovarian cancer. Ann Oncol 12:337–341[Abstract/Free Full Text]
87. Rodriguez C, Patel AV, Calle EE, Jacob EJ, Thun MJ 2001 Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. JAMA 285:1460–1465[Abstract/Free Full Text]
88. Choi KC, Kang SK, Tai CJ, Auersperg N, Leung PC 2001 Estradiol up-regulates antiapoptotic Bcl-2 messenger ribonucleic acid and protein in tumorigenic ovarian surface epithelium cells. Endocrinology 142:2351–2360[Abstract/Free Full Text]
89. Syed V, Ulinski G, Mok SC, Yiu GK, Ho SM 2001 Expression of gonadotropin receptor and growth responses to key reproductive hormones in normal and malignant human ovarian surface epithelial cells. Cancer Res 61:6768–6776[Abstract/Free Full Text]
90. Weiss G, Skurnick JH, Goldsmith LT, Santoro NF, Park SJ 2004 Menopause and hypothalamic-pituitary sensitivity to estrogen. JAMA 292:2991–2996[Abstract/Free Full Text]
91. Rao BR, Slotman BJ 1991 Endocrine factors in common epithelial ovarian cancer. Endocr Rev 12:14–26[Abstract/Free Full Text]
92. Shoham Z 1994 Epidemiology, etiology, and fertility drugs in ovarian epithelial carcinoma: where are we today? Fertil Steril 62:433–448[Medline]
93. Balen A 1995 The effects of ovulation induction with gonadotrophins on the ovary and uterus and implications for assisted reproduction. Hum Reprod 10:2233–2237[Free Full Text]
94. Modan B, Ron E, Lerner-Geva L, Blumstein T, Menczer J, Rabinovici J, Oelsner G, Freedman L, Mashiach S, Lunenfeld B 1998 Cancer incidence in a cohort of infertile women. Am J Epidemiol 147:1038–1042[Abstract/Free Full Text]
95. Potashnik G, Lerner-Geva L, Genkin L, Chetrit A, Lunenfeld E, Porath A 1999 Fertility drugs and the risk of breast and ovarian cancers: results of a long-term follow-up study. Fertil Steril 71:853–859[CrossRef][Medline]
96. Doyle P, Maconochie N, Beral V, Swerdlow AJ, Tan SL 2002 Cancer incidence following treatment for infertility at a clinic in the UK. Hum Reprod 17:2209–2213[Abstract/Free Full Text]
97. Brinton LA, Lamb EJ, Moghissi KS, Scoccia B, Althuis MD, Mabie JE, Westhoff CL 2004 Ovarian cancer risk after the use of ovulation-stimulating drugs. Obstet Gynecol 103:1194–1203[CrossRef][Medline]
98. Konishi I 2006 Gonadotropins and ovarian carcinogenesis: a new era of basic research and its clinical implications. Int J Gynecol Cancer 16:16–22[CrossRef][Medline]
99. Kashyap S, Moher D, Fung MF, Rosenwaks Z 2004 Assisted reproductive technology and the incidence of ovarian cancer: a meta-analysis. Obstet Gynecol 103:785–794[Medline]
100. Lukanova A, Kaaks R 2005 Endogenous hormones and ovarian cancer: epidemiology and current hypotheses. Cancer Epidemiol Biomarkers Prev 14:98–107[Abstract/Free Full Text]
101. Shushan A, Paltiel O, Iscovich J, Elchalal U, Peretz T, Schenker JG 1996 Human menopausal gonadotropin and the risk of epithelial ovarian cancer. Fertil Steril 65:13–18[Medline]
102. Biskind GR, Biskind, MS 1948 Atrophy of ovaries transplanted to the spleen in unilaterally castrated rats; proliferative changes following subsequent removal of intact ovary. Science 108:137–138[Abstract/Free Full Text]
103. Matzuk MM, Finegold MJ, Su JG, Hsueh AJ, Bradley A 1992 -Inhibin is a tumour-suppressor gene with gonadal specificity in mice. Nature 360:313–319[CrossRef][Medline]
104. Kumar TR, Palapattu G, Wang P, Woodruff TK, Boime I, Byrne MC, Matzuk MM 1999 Transgenic models to study gonadotropin function: the role of follicle-stimulating hormone in gonadal growth and tumorigenesis. Mol Endocrinol 13:851–865[Abstract/Free Full Text]
105. Risma KA, Clay CM, Nett TM, Wagner T, Yun J, Nilson JH 1995 Targeted overexpression of luteinizing hormone in transgenic mice leads to infertility, polycystic ovaries, and ovarian tumors. Proc Natl Acad Sci USA 92:1322–1326[Abstract/Free Full Text]
106. Keri RA, Lozada KL, Abdul-Karim FW, Nadeau JH, Nilson JH 2000 Luteinizing hormone induction of ovarian tumors: oligogenic differences between mouse strains dictates tumor disposition. Proc Natl Acad Sci USA 97:383–387[Abstract/Free Full Text]
107. Kananen K, Markkula M, Rainio E, Su JG, Hsueh AJ, Huhtaniemi IT 1995 Gonadal tumorigenesis in transgenic mice bearing the mouse inhibin -subunit promoter/simian virus T-antigen fusion gene: characterization of ovarian tumors and establishment of gonadotropin-responsive granulosa cell lines. Mol Endocrinol 9:616–627[Abstract/Free Full Text]
108. Stewart SL, Querec TD, Gruver BN, O’Hare B, Babb JS, Patriotis C 2004 Gonadotropin and steroid hormones stimulate proliferation of the rat ovarian surface epithelium. J Cell Physiol 198:119–124[CrossRef][Medline]
109. Davies BR, Finnigan DS, Smith SK, Ponder BA 1999 Administration of gonadotropins stimulates proliferation of normal mouse ovarian surface epithelium. Gynecol Endocrinol 13:75–81[Medline]
110. Osterholzer HO, Johnson JH, Nicosia SV 1985 An autoradiographic study of rabbit ovarian surface epithelium before and after ovulation. Biol Reprod 33:729–738[Abstract]
111. Burdette JE, Kurley SJ, Kilen SM, Mayo KE, Woodruff TK 2006 Gonadotropin-induced superovulation drives ovarian surface epithelia proliferation in CD1 mice. Endocrinology 147:2338–2345[Abstract/Free Full Text]
112. Godwin AK, Testa JR, Handel LM, Liu Z, Vanderveer LA, Tracey PA, Hamilton TC 1992 Spontaneous transformation of rat ovarian surface epithelial cells: association with cytogenetic changes and implications of repeated ovulation in the etiology of ovarian cancer. J Natl Cancer Inst 84:592–601[Abstract/Free Full Text]
113. Roby KF, Taylor CC, Sweetwood JP, Cheng Y, Pace JL, Tawfik O, Persons DL, Smith PG, Terranova PF 2000 Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis 21:585–591[Abstract/Free Full Text]
114. Celik C, Gezginc K, Aktan M, Acar A, Yaman ST, Gungor S, Akyurek C 2004 Effects of ovulation induction on ovarian morphology: an animal study. Int J Gynecol Cancer 14:600–606[CrossRef][Medline]
115. Adams AT, Auersperg N 1981 Transformation of cultured rat ovarian surface epithelial cells by Kirsten murine sarcoma virus. Cancer Res 41:2063–2072[Abstract/Free Full Text]
116. Davies BR, Worsley SD, Ponder BA 1998 Expression of E-cadherin, -catenin and ß-catenin in normal ovarian surface epithelium and epithelial ovarian cancers. Histopathology 32:69–80[CrossRef][Medline]
117. McNeil L, Hobson S, Nipper V, Rodland KD 1998 Functional calcium-sensing receptor expression in ovarian surface epithelial cells. Am J Obstet Gynecol 178:305–313[CrossRef][Medline]
118. Stewart SL, Querec TD, Ochman AR, Gruver BN, Bao R, Babb JS, Wong TS, Koutroukides T, Pinnola AD, Klein-Szanto A, Hamilton TC, Patriotis C 2004 Characterization of a carcinogenesis rat model of ovarian preneoplasia and neoplasia. Cancer Res 64:8177–8183[Abstract/Free Full Text]
119. Schiffenbauer YS, Abramovitch R, Meir G, Nevo N, Holzinger M, Itin A, Keshet E, Neeman M 1997 Loss of ovarian function promotes angiogenesis in human ovarian carcinoma. Proc Natl Acad Sci USA 94:13203–13208[Abstract/Free Full Text]
120. Arslan AA, Zeleniuch-Jacquotte A, Lundin E, Micheli A, Lukanova A, Afanasyeva Y, Lenner P, Krogh V, Muti P, Rinaldi S, Kaaks R, Berrino F, Hallmans G, Toniolo P 2003 Serum follicle-stimulating hormone and risk of epithelial ovarian cancer in postmenopausal women. Cancer Epidemiol Biomarkers Prev 12:1531–1535[Abstract/Free Full Text]
121. Kramer S, Leeker M, Jager W 1998 Gonadotropin levels in ovarian cyst fluids: a predictor of malignancy? Int J Biol Markers 13:165–168[Medline]
122. Blaakaer J, Djursing H, Hording U, Bennett P, Toftager-Larsen K, Bock JE, Lebech PE 1992 The pituitary-gonadal axis in women with benign or malignant ovarian tumors. Acta Endocrinol (Copenh) 127:127–130[Abstract/Free Full Text]
123. Helzlsouer KJ, Alberg AJ, Gordon GB, Longcope C, Bush TL, Hoffman SC, Comstock GW 1995 Serum gonadotropins and steroid hormones and the development of ovarian cancer. JAMA 274:1926–1930[Abstract/Free Full Text]
124. Akhmedkhanov A, Toniolo P, Zeleniuch-Jacquotte A, Pettersson KS, Huhtaniemi IT 2001 Luteinizing hormone, its ß-subunit variant, and epithelial ovarian cancer: the gonadotropin hypothesis revisited. Am J Epidemiol 154:43–49[Abstract/Free Full Text]
125. Marcillac I, Troalen F, Bidart JM, Ghillani P, Ribrag V, Escudier B, Malassagne B, Droz JP, Lhomme C, Rougier P, Duvillard P, Prade M, Lugagne P-M, Richard F, Poynard T, Bohuon C, Wands J, Bellet D 1992 Free human chorionic gonadotropin ß subunit in gonadal and nongonadal neoplasms. Cancer Res 52:3901–3907[Abstract/Free Full Text]
126. Alfthan H, Haglund C, Roberts P, Stenman UH 1992 Elevation of free ß subunit of human choriogonadotropin and core ß fragment of human choriogonadotropin in the serum and urine of patients with malignant pancreatic and biliary disease. Cancer Res 52:4628–4633[Abstract/Free Full Text]
127. Cole LA, Schwartz PE, Wang YX 1988 Urinary gonadotropin fragments (UGF) in cancers of the female reproductive system. I. Sensitivity and specificity, comparison with other markers. Gynecol Oncol 31:82–90[CrossRef][Medline]
128. Vartiainen J, Lehtovirta P, Finne P, Stenman UH, Alfthan H 2001 Preoperative serum concentration of hCGß as a prognostic factor in ovarian cancer. Int J Cancer 95:313–316[CrossRef][Medline]
129. Nowak-Markwitz E, Jankowska A, Andrusiewicz M, Szczerba A 2004 Expression of ß-human chorionic gonadotropin in ovarian cancer tissue. Eur J Gynaecol Oncol 25:465–469[Medline]
130. Jernstrom H, Borg K, Olsson H 2005 High follicular phase luteinizing hormone levels in young healthy BRCA1 mutation carriers: implications for breast and ovarian cancer risk. Mol Genet Metab 86:320–327[CrossRef][Medline]
131. Halperin R, Pansky M, Vaknin Z, Zehavi S, Bukovsky I, Schneider D 2003 Luteinizing hormone in peritoneal and ovarian cyst fluids: a predictor of ovarian carcinoma. Eur J Obstet Gynecol Reprod Biol 110:207–210[CrossRef][Medline]
132. Chudecka-Glaz A, Rzepka-Gorska I, Kosmowska B 2004 Gonadotropin (LH, FSH) levels in serum and cyst fluid in epithelial tumors of the ovary. Arch Gynecol Obstet 270:151–156[CrossRef][Medline]
133. Rzepka-Gorska I, Chudecka-Glaz A, Kosmowska B 2004 FSH and LH serum/tumor fluid ratios and malignant tumors of the ovary. Endocr Relat Cancer 11:315–321[Abstract]
134. Zheng W, Lu JJ, Luo F, Zheng Y, Feng Y, Felix JC, Lauchlan SC, Pike MC 2000 Ovarian epithelial tumor growth promotion by follicle-stimulating hormone and inhibition of the effect by luteinizing hormone. Gynecol Oncol 76:80–88[CrossRef][Medline]
135. Kobayashi F, Monma C, Nanbu K, Konishi I, Sagawa N, Mori T 1996 Rapid growth of an ovarian clear cell carcinoma expressing LH/hCG receptor arising from endometriosis during early pregnancy. Gynecol Oncol 62:309–313[CrossRef][Medline]
136. Parrott JA, Doraiswamy V, Kim G, Mosher R, Skinner MK 2001 Expression and actions of both the follicle stimulating hormone receptor and the luteinizing hormone receptor in normal ovarian surface epithelium and ovarian cancer. Mol Cell Endocrinol 172:213–222[CrossRef][Medline]
137. Minegishi T, Kameda T, Hirakawa T, Abe K, Tano M, Ibuki Y 2000 Expression of gonadotropin and activin receptor messenger ribonucleic acid in human ovarian epithelial neoplasms. Clin Cancer Res 6:2764–2770[Abstract/Free Full Text]
138. Mandai M, Konishi I, Kuroda H, Fukumoto M, Komatsu T, Yamamoto S, Nanbu K, Rao CV, Mori T 1997 Messenger ribonucleic acid expression of LH/hCG receptor gene in human ovarian carcinomas. Eur J Cancer 33:1501–1507[CrossRef][Medline]
139. Rajaniemi H, Kauppila A, Ronnberg L, Selander K, Pystynen P 1981 LH(hCG) receptor in benign and malignant tumors of human ovary. Acta Obstet Gynecol Scand Suppl 101:83–86[Medline]
140. Lu JJ, Zheng Y, Kang X, Yuan JM, Lauchlan SC, Pike MC, Zheng W 2000 Decreased luteinizing hormone receptor mRNA expression in human ovarian epithelial cancer. Gynecol Oncol 79:158–168[CrossRef][Medline]
141. Choi KC, Kang SK, Tai CJ, Auersperg N, Leung PC 2002 Follicle-stimulating hormone activates mitogen-activated protein kinase in preneoplastic and neoplastic ovarian surface epithelial cells. J Clin Endocrinol Metab 87:2245–2253[Abstract/Free Full Text]
142. Wang J, Lin L, Parkash V, Schwartz PE, Lauchlan SC, Zheng W 2003 Quantitative analysis of follicle-stimulating hormone receptor in ovarian epithelial tumors: a novel approach to explain the field effect of ovarian cancer development in secondary Müllerian systems. Int J Cancer 103:328–334[CrossRef][Medline]
143. Ji Q, Liu PI, Chen PK, Aoyama C 2004 Follicle stimulating hormone-induced growth promotion and gene expression profiles on ovarian surface epithelial cells. Int J Cancer 112:803–814[CrossRef][Medline]
144. Choi JH, Choi KC, Auersperg N, Leung PC 2004 Overexpression of follicle-stimulating hormone receptor activates oncogenic pathways in preneoplastic ovarian surface epithelial cells. J Clin Endocrinol Metab 89:5508–5516[Abstract/Free Full Text]
145. Wunsch A, Ahda Y, Banaz-Yasar F, Sonntag B, Nieschlag E, Simoni M, Gromoll J 2005 Single-nucleotide polymorphisms in the promoter region influence the expression of the human follicle-stimulating hormone receptor. Fertil Steril 84:446–453[CrossRef][Medline]
146. Griswold MD, Kim JS 2001 Site-specific methylation of the promoter alters deoxyribonucleic acid-protein interactions and prevents follicle-stimulating hormone receptor gene transcription. Biol Reprod 64:602–610[Abstract/Free Full Text]
147. Steinmeyer C, Berkholz A, Gebauer G, Jager W 2003 The expression of hCG receptor mRNA in four human ovarian cancer cell lines varies considerably under different experimental conditions. Tumour Biol 24:13–22[CrossRef][Medline]
148. Themmen APN, Huhtaniemi IT 2000 Mutations of gonadotropins and gonadotropin receptors: elucidating the physiology and pathophysiology of pituitary-gonadal function. Endocr Rev 21:551–583[Abstract/Free Full Text]
149. Shenker A, Laue L, Kosugi S, Merendino Jr JJ, Minegishi T, Cutler Jr GB 1993 A constitutively activating mutation of the luteinizing hormone receptor in familial male precocious puberty. Nature 365:652–654[CrossRef][Medline]
150. Aittomaki K, Lucena JL, Pakarinen P, Sistonen P, Tapanainen J, Gromoll J, Kaskikari R, Sankila EM, Lehvaslaiho H, Engel AR, Nieschlag E, Huhtaniemi I, de la Chapelle A 1995 Mutation in the follicle-stimulating hormone receptor gene causes hereditary hypergonadotropic ovarian failure. Cell 82:959–968[CrossRef][Medline]
151. Aittomaki K, Herva R, Stenman UH, Juntunen K, Ylostalo P, Hovatta O, de la Chapelle A 1996 Clinical features of primary ovarian failure caused by a point mutation in the follicle-stimulating hormone receptor gene. J Clin Endocrinol Metab 81:3722–3726[Abstract]
152. Gromoll J, Simoni M 2005 Genetic complexity of FSH receptor function. Trends Endocrinol Metab 16:368–373[CrossRef][Medline]
153. Ichikawa Y, Yoshida S, Suzuki H, Nishida M, Tsunoda H, Kubo T, Miwa M, Uchida K 1996 Mutation analysis of gonadotropin receptor and G protein genes in various types of human ovarian tumors. Jpn J Clin Oncol 26:298–302[Abstract/Free Full Text]
154. Perez Mayorga M, Gromoll J, Behre HM, Gassner C, Nieschlag E, Simoni M 2000 Ovarian response to follicle-stimulating hormone (FSH) stimulation depends on the FSH receptor genotype. J Clin Endocrinol Metab 85:3365–3369[Abstract/Free Full Text]
155. Greb RR, Grieshaber K, Gromoll J, Sonntag B, Nieschlag E, Kiesel L, Simoni M 2005 A common single nucleotide polymorphism in exon 10 of the human follicle stimulating hormone receptor is a major determinant of length and hormonal dynamics of the menstrual cycle. J Clin Endocrinol Metab 90:4866–4872[Abstract/Free Full Text]
156. Yang CQ, Chan KYK, Ngan HYS, Khoo US, Chiu PM, Chan QKY, Xue WC, Cheung ANY 2006 Single nucleotide polymorphisms of follicle stimulating hormone receptor are associated with ovarian cancer susceptibility. Carcinogenesis 27:1502–1506[Abstract/Free Full Text]
157. Ho SM, Lau KM, Mok SC, Syed V 2003 Profiling follicle stimulating hormone-induced gene expression changes in normal and malignant human ovarian surface epithelial cells. Oncogene 22:4243–4256[CrossRef][Medline]
158. Rimon E, Sasson R, Dantes A, Land-Bracha A, Amsterdam A 2004 Gonadotropin-induced gene regulation in human granulosa cells obtained from IVF patients: modulation of genes coding for growth factors and their receptors and genes involved in cancer and other diseases. Int J Oncol 24:1325–1338[Medline]
159. Espey LL, Richards JS 2002 Temporal and spatial patterns of ovarian gene transcription following an ovulatory dose of gonadotropin in the rat. Biol Reprod 67:1662–1670[Abstract/Free Full Text]
160. Doraiswamy V, Parrott JA, Skinner MK 2000 Expression and action of transforming growth factor in normal ovarian surface epithelium and ovarian cancer. Biol Reprod 63:789–796[Abstract/Free Full Text]
161. Wimalasena J, Dostal R, Meehan D 1992 Gonadotropins, estradiol, and growth factors regulate epithelial ovarian cancer cell growth. Gynecol Oncol 46:345–350[CrossRef][Medline]
162. Ohtani K, Sakamoto H, Kikuchi A, Nakayama Y, Idei T, Igarashi N, Matukawa T, Satoh K 2001 Follicle-stimulating hormone promotes the growth of human epithelial ovarian cancer cells through the protein kinase C-mediated system. Cancer Lett 166:207–213[CrossRef][Medline]
163. Kraemer S, Jaeger WH, Lang N 2001 Growth regulation effects of gonadotropin induced steroidogenic response in human ovarian cancer. Anticancer Res 21:2005–2010[Medline]
164. Gubbay O, Guo W, Rae MT, Niven D, Howie AF, McNeilly AS, Xu L, Hillier SG 2004 Anti-inflammatory and proliferative responses in human and ovine ovarian surface epithelial cells. Reproduction 128:607–614[Abstract/Free Full Text]
165. Edmondson RJ, Monaghan JM, Davies BR 2006 Gonadotropins mediate DNA synthesis and protection from spontaneous cell death in human ovarian surface epithelium. Int J Gynecol Cancer 16:171–177[CrossRef][Medline]
166. Wright JW, Toth-Fejel S, Stouffer RL, Rodland KD 2002 Proliferation of rhesus ovarian surface epithelial cells in culture: lack of mitogenic response to steroid or gonadotropic hormones. Endocrinology 143:2198–2207[Abstract/Free Full Text]
167. Ivarsson K, Sundfeldt K, Brannstrom M, Hellberg P, Janson PO 2001 Diverse effects of FSH and LH on proliferation of human ovarian surface epithelial cells. Hum Reprod 16:18–23[Abstract/Free Full Text]
168. Pon YL, Auersperg N, Wong AS 2005 Gonadotropins regulate N-cadherin-mediated human ovarian surface epithelial cell survival at both post-translational and transcriptional levels through a cyclic AMP/protein kinase A pathway. J Biol Chem 280:15438–15448[Abstract/Free Full Text]
169. Kurbacher CM, Jager W, Kurbacher JA, Bittl A, Wildt L, Lang N 1995 Influence of human luteinizing hormone on cell growth and CA 125 secretion of primary epithelial ovarian carcinomas in vitro. Tumour Biol 16:374–384[Medline]
170. Tashiro H, Katabuchi H, Begum M, Li X, Nitta M, Ohtake H, Okamura H 2003 Roles of luteinizing hormone/chorionic gonadotropin receptor in anchorage-dependent and -independent growth in human ovarian surface epithelial cell lines. Cancer Sci 94:953–959[CrossRef][Medline]
171. Kuroda H, Mandai M, Konishi I, Yura Y, Tsuruta Y, Hamid AA, Nanbu K, Matsushita K, Mori T 1998 Human chorionic gonadotropin (hCG) inhibits cisplatin-induced apoptosis in ovarian cancer cells: possible role of up-regulation of insulin-like growth factor-1 by hCG. Int J Cancer 76:571–578[CrossRef][Medline]
172. Kuroda H, Mandai M, Konishi I, Tsuruta Y, Kusakari T, Kariya M, Fujii S 2001 Human ovarian surface epithelial (OSE) cells express LH/hCG receptors, and hCG inhibits apoptosis of OSE cells via up-regulation of insulin-like growth factor-1. Int J Cancer 91:309–315[CrossRef][Medline]
173. Wimalasena J, Meehan D, Dostal R, Foster JS, Cameron M, Smith M 1993 Growth factors interact with estradiol and gonadotropins in the regulation of ovarian cancer cell growth and growth factor receptors. Oncol Res 5:325–337[Medline]
174. Tourgeman DE, Lu JJ, Boostanfar R, Amezcua C, Felix JC, Paulson RJ 2002 Human chorionic gonadotropin suppresses ovarian epithelial neoplastic cell proliferation in vitro. Fertil Steril 78:1096–1099[CrossRef][Medline]
175. Pon YL, Wong AS 2006 Gonadotropin-induced apoptosis in human ovarian surface epithelial cells is associated with cyclooxygenase-2 upregulation via the ß-catenin/T-cell factor signaling pathway. Mol Endocrinol 20:3336–3350[Abstract/Free Full Text]
176. Wimalasena J, Meehan D, Cavallo C 1991 Human epithelial ovarian cancer cell steroid secretion and its control by gonadotropins. Gynecol Oncol 41:56–63[CrossRef][Medline]
177. Zheng W, Lu JJ, Luo F, Hsieh J, Wang CY, Zhang C, Chang L, Cho MM, Stanczyk FZ 2000 Tumor stroma as the main source of inhibin production in ovarian epithelial tumors. Am J Reprod Immunol 44:104–113[Medline]
178. Syed V, Ulinski G, Mok SC, Ho SM 2002 Reproductive hormone-induced, STAT3-mediated interleukin 6 action in normal and malignant human ovarian surface epithelial cells. J Natl Cancer Inst 94:617–629[Abstract/Free Full Text]
179. Hsueh AJ, Adashi EY, Jones PB, Welsh Jr TH 1984 Hormonal regulation of the differentiation of cultured ovarian granulosa cells. Endocr Rev 5:76–127[Abstract/Free Full Text]
180. Sekar N, Veldhuis JD 2001 Concerted transcriptional activation of the low density lipoprotein receptor gene by insulin and luteinizing hormone in cultured porcine granulosa-luteal cells: possible convergence of protein kinase A, phosphatidylinositol 3-kinase, and mitogen-activated protein kinase signaling pathways. Endocrinology 142:2921–2928[Abstract/Free Full Text]
181. Das S, Maizels ET, DeManno D, St Clair E, Adam SA, Hunzicker-Dunn M 1996 A stimulatory role of cyclic adenosine 3',5'-monophosphate in follicle-stimulating hormone-activated mitogen-activated protein kinase signaling pathway in rat ovarian granulosa cells. Endocrinology 137:967–974[Abstract]
182. Cameron MR, Foster JS, Bukovsky A, Wimalasena J 1996 Activation of mitogen-activated protein kinases by gonadotropins and cyclic adenosine 5'-monophosphates in porcine granulosa cells. Biol Reprod 55:111–119[Abstract]
183. Pennybacker M, Herman B 1991 Follicle-stimulating hormone increases c-fos mRNA levels in rat granulosa cells via a protein kinase C-dependent mechanism. Mol Cell Endocrinol 80:11–20[CrossRef][Medline]
184. Babu PS, Krishnamurthy H, Chedrese PJ, Sairam MR 2000 Activation of extracellular-regulated kinase pathways in ovarian granulosa cells by the novel growth factor type 1 follicle-stimulating hormone receptor. Role in hormone signaling and cell proliferation. J Biol Chem 275:27615–27626[Abstract/Free Full Text]
185. Alam H, Maizels ET, Park Y, Ghaey S, Feiger ZJ, Chandel NS, Hunzicker-Dunn M 2004 Follicle-stimulating hormone activation of hypoxia-inducible factor-1 by the phosphatidylinositol 3-kinase/AKT/Ras homolog enriched in brain (Rheb)/mammalian target of rapamycin (mTOR) pathway is necessary for induction of select protein markers of follicular differentiation. J Biol Chem 279:19431–19440[Abstract/Free Full Text]
186. Cunningham MA, Zhu Q, Unterman TG, Hammond JM 2003 Follicle-stimulating hormone promotes nuclear exclusion of the forkhead transcription factor FoxO1a via phosphatidylinositol 3-kinase in porcine granulosa cells. Endocrinology 144:5585–5594[Abstract/Free Full Text]
187. Gonzalez-Robayna IJ, Falender AE, Ochsner S, Firestone GL, Richards JS 2000 Follicle-stimulating hormone (FSH) stimulates phosphorylation and activation of protein kinase B (PKB/Akt) and serum and glucocorticoid-induced kinase (Sgk): evidence for A kinase-independent signaling by FSH in granulosa cells. Mol Endocrinol 14:1283–1300[Abstract/Free Full Text]
188. Herrlich A, Kuhn B, Grosse R, Schmid A, Schultz G, Gudermann T 1996 Involvement of Gs and Gi proteins in dual coupling of the luteinizing hormone receptor to adenylyl cyclase and phospholipase C. J Biol Chem 271:16764–16772[Abstract/Free Full Text]
189. Chiang M, Strong JA, Asem EK 1997 Luteinizing hormone activates chloride currents in hen ovarian granulosa cells. Comp Biochem Physiol A Physiol 116:361–368[Medline]
190. Flores JA, Leong DA, Veldhuis JD 1992 Is the calcium signal induced by follicle-stimulating hormone in swine granulosa cells mediated by adenosine cyclic 3',5'-monophosphate-dependent protein kinase? Endocrinology 130:1862–1866[Abstract/Free Full Text]
191. Choi KC, Auersperg N, Leung PC 2001 Expression and antiproliferative effect of a second form of gonadotropin-releasing hormone in normal and neoplastic ovarian surface epithelial cells. J Clin Endocrinol Metab 86:5075–5078[Abstract/Free Full Text]
192. Choi JH, Choi KC, Auersperg N, Leung PC 2005 Gonadotropins upregulate the epidermal growth factor receptor through activation of mitogen-activated protein kinases and phosphatidyl-inositol-3-kinase in human ovarian surface epithelial cells. Endocr Relat Cancer 12:407–421[Abstract/Free Full Text]
193. Altschuler DL, Peterson SN, Ostrowski MC, Lapetina EG 1995 Cyclic AMP-dependent activation of Rap1b. J Biol Chem 270:10373–10376[Abstract/Free Full Text]
194. Nechamen CA, Thomas RM, Cohen BD, Acevedo G, Poulikakos PI, Testa JR, Dias JA 2004 Human follicle-stimulating hormone (FSH) receptor interacts with the adaptor protein APPL1 in HEK 293 cells: potential involvement of the PI3K pathway in FSH signaling. Biol Reprod 71:629–636[Abstract/Free Full Text]
195. Kawasaki H, Springett GM, Mochizuki N, Toki S, Nakaya M, Matsuda M, Housman DE, Graybiel AM 1998 A family of cAMP-binding proteins that directly activate Rap1. Science 282:2275–2279[Abstract/Free Full Text]
196. de Rooij J, Zwartkruis FJ, Verheijen MH, Cool RH, Nijman SM, Wittinghofer A, Bos JL 1998 Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP. Nature 396:474–477[CrossRef][Medline]
197. Gille H, Downward J 1999 Multiple ras effector pathways contribute to G(1) cell cycle progression. J Biol Chem 274:22033–22040[Abstract/Free Full Text]
198. Rangarajan S, Enserink JM, Kuiperij HB, de Rooij J, Price LS, Schwede F, Bos JL 2003 Cyclic AMP induces integrin-mediated cell adhesion through Epac and Rap1 upon stimulation of the ß 2-adrenergic receptor. J Cell Biol 160:487–493[Abstract/Free Full Text]
199. Mitsuuchi Y, Johnson SW, Sonoda G, Tanno S, Golemis EA, Testa JR 1999 Identification of a chromosome 3p14.3–21.1 gene, APPL, encoding an adaptor molecule that interacts with the oncoprotein-serine/threonine kinase AKT2. Oncogene 18:4891–4898[CrossRef][Medline]
200. Katsaros D, Fracchioli S, Arese P, Enria R, Cassinelli P, Mingrone K, Piccinno R, Rigault de la Longrais IA, Massobrio M 1999 Chemoresistance in ovarian cancer. State of the art and future prospects. Minerva Ginecol 51:483–499[Medline]
201. Kikuchi Y 2001 [The mechanism of cisplatin-resistance in ovarian cancer]. Hum Cell 14:115–133[Medline]
202. Tilly JL, Tilly KI, Kenton ML, Johnson AL 1995 Expression of members of the bcl-2 gene family in the immature rat ovary: equine chorionic gonadotropin-mediated inhibition of granulosa cell apoptosis is associated with decreased bax and constitutive bcl-2 and bcl-xlong messenger ribonucleic acid levels. Endocrinology 136:232–241[Abstract]
203. Wang Y, Rippstein PU, Tsang BK 2003 Role and gonadotrophic regulation of X-linked inhibitor of apoptosis protein expression during rat ovarian follicular development in vitro. Biol Reprod 68:610–619[Abstract/Free Full Text]
204. Slot KA, de Boer-Brouwer M, Houweling M, Vaandrager AB, Dorrington JH, Teerds KJ 2006 Luteinizing hormone inhibits Fas-induced apoptosis in ovarian surface epithelial cell lines. J Endocrinol 188:227–239[Abstract/Free Full Text]
205. Huang CF, Liu DY, Xu WH, Shen K 2003 Protective effect of follicle stimulating hormone on apoptosis of human epithelial ovarian cancer cell induced by cisplatin. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 25:443–446[Medline]
206. Huang CF, Liu DY, Shen K 2003 Follicle stimulating hormone inhibits cisplatin induced apoptosis in ovarian cancer cells. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 25:447–450[Medline]
207. Zygmunt M, Herr F, Keller-Schoenwetter S, Kunzi-Rapp K, Munstedt K, Rao CV, Lang U, Preissner KT 2002 Characterization of human chorionic gonadotropin as a novel angiogenic factor. J Clin Endocrinol Metab 87:5290–5296[Abstract/Free Full Text]
208. Schiffenbauer YS, Meir G, Maoz M, Even-Ram SC, Bar-Shavit R, Neeman M 2002 Gonadotropin stimulation of MLS human epithelial ovarian carcinoma cells augments cell adhesion mediated by CD44 and by (v)-integrin. Gynecol Oncol 84:296–302[CrossRef][Medline]
209. Wang J, Luo F, Lu JJ, Chen PK, Liu P, Zheng W 2002 VEGF expression and enhanced production by gonadotropins in ovarian epithelial tumors. Int J Cancer 97:163–167[CrossRef][Medline]
210. Choi JH, Choi KC, Auersperg N, Leung PC 2006 Gonadotropins activate proteolysis and increase invasion through protein kinase A and phosphatidylinositol 3-kinase pathways in human epithelial ovarian cancer cells. Cancer Res 66:3912–3920[Abstract/Free Full Text]
211. McDonnel AC, Murdoch WJ 2001 High-dose progesterone inhibition of urokinase secretion and invasive activity by SKOV-3 ovarian carcinoma cells: evidence for a receptor-independent nongenomic effect on the plasma membrane. J Steroid Biochem Mol Biol 78:185–191[CrossRef][Medline]
212. Vaitukaitis JL 1974 Human chorionic gonadotropin as a tumor marker. Ann Clin Lab Sci 4:276–280[Abstract]
213. Ind T, Iles R, Shepherd J, Chard T 1997 Serum concentrations of cancer antigen 125, placental alkaline phosphatase, cancer-associated serum antigen and free ß human chorionic gonadotrophin as prognostic markers for epithelial ovarian cancer. Br J Obstet Gynaecol 104:1024–1029[Medline]
214. Cramer DW, Petterson KS, Barbieri RL, Huhtaniemi IT 2000 Reproductive hormones, cancers, and conditions in relation to a common genetic variant of luteinizing hormone. Hum Reprod 15:2103–2107[Abstract/Free Full Text]
215. Ries LA, Harkins D, Krapcho M, Mariotto A, Miller BA, Feuer EJ, Clegg L, Eisner MP, Horner MJ, Howlader N, Hayat M, Hankey BF, Edwards BK 2006 SEER Cancer Statistics Review, 1975–2003. Bethesda, MD: National Institutes of Health
216. Reimer T, Gerber B, Kunkel S, Luettich K 1997 Estradiol, gonadotropins, and tumor markers in ovarian cyst fluid. Acta Obstet Gynecol Scand 76:478–483[Medline]
217. Emons G, Ortmann O, Teichert HM, Fassl H, Lohrs U, Kullander S, Kauppila A, Ayalon D, Schally A, Oberheuser F 1996 Luteinizing hormone-releasing hormone agonist triptorelin in combination with cytotoxic chemotherapy in patients with advanced ovarian carcinoma. A prospective double blind randomized trial. Decapeptyl Ovarian Cancer Study Group. Cancer 78:1452–1460[CrossRef][Medline]
218. du Bois A, Meier W, Luck HJ, Emons G, Moebus V, Schroeder W, Costa S, Bauknecht T, Olbricht S, Jackisch C, Richter B, Wagner U 2002 Chemotherapy versus hormonal treatment in platinum- and paclitaxel-refractory ovarian cancer: a randomised trial of the German Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Ovarian Cancer. Ann Oncol 13:251–257[Abstract/Free Full Text]
219. Paskeviciute L, Roed H, Engelholm S 2002 No rules without exception: long-term complete remission observed in a study using a LH-RH agonist in platinum-refractory ovarian cancer. Gynecol Oncol 86:297–301[CrossRef][Medline]
220. Balbi G, Piano LD, Cardone A, Cirelli G 2004 Second-line therapy of advanced ovarian cancer with GnRH analogs. Int J Gynecol Cancer 14:799–803[CrossRef][Medline]
221. Duffaud F, van der Burg ME, Namer M, Vergote I, Willemse PHB, ten Bokkel Huinink W, Guastalla JP, Nooij, Kerbrat P, Piccart M, Tumolo S, Favalli G, van der Vange N, Lacave AJ, Wils J, Splinter TA, Einhorn N, Roozendaal KJ, Rosso R, Vermorken JB 2001 D-TRP-6-LHRH (Triptorelin) is not effective in ovarian carcinoma: an EORTC Gynaecological Cancer Co-operative Group Study. Anticancer Drugs 12:159–162[CrossRef][Medline]
222. Verschraegen CF, Westphalen S, Hu W, Loyer E, Kudelka A, Volker P, Kavanagh J, Steger M, Schulz KD, Emons G 2003 Phase II study of cetrorelix, a luteinizing hormone-releasing hormone antagonist in patients with platinum-resistant ovarian cancer. Gynecol Oncol 90:552–559[CrossRef][Medline]
223. Chatzistamou I, Schally AV, Szepeshazi K, Groot K, Hebert F, Arencibia JM 2001 Inhibition of growth of ES-2 human ovarian cancers by bombesin antagonist RC-3095, and luteinizing hormone-releasing hormone antagonist Cetrorelix. Cancer Lett 171:37–45[CrossRef][Medline]
224. Hasan J, Ton N, Mullamitha S, Clamp A, McNeilly A, Marshall E, Jayson GC 2005 Phase II trial of tamoxifen and goserelin in recurrent epithelial ovarian cancer. Br J Cancer 93:647–651[CrossRef][Medline]
225. Rzepka-Gorska I, Chudecka-Glaz A, Kosmider M, Malecha J 2003 GnRH analogues as an adjuvant therapy for ovarian cancer patients. Int J Gynaecol Obstet 81:199–205[CrossRef][Medline]
226. Emons G, Ortmann O, Becker M, Irmer G, Springer B, Laun R, Holzel F, Schulz KD, Schally AV 1993 High affinity binding and direct antiproliferative effects of LHRH analogues in human ovarian cancer cell lines. Cancer Res 53:5439–5446[Abstract/Free Full Text]
227. Peterson CM, Jolles CJ, Carrell DT, Straight RC, Jones KP, Poulson Jr AM, Hatasaka HH 1994 GnRH agonist therapy in human ovarian epithelial carcinoma (OVCAR-3) heterotransplanted in the nude mouse is characterized by latency and transience. Gynecol Oncol 52:26–30[CrossRef][Medline]
228. Imai A, Takagi H, Furui T, Horibe S, Fuseya T, Tamaya T 1996 Evidence for coupling of phosphotyrosine phosphatase to gonadotropin-releasing hormone receptor in ovarian carcinoma membrane. Cancer 77:132–137[CrossRef][Medline]
229. Kimura A, Ohmichi M, Kurachi H, Ikegami H, Hayakawa J, Tasaka K, Kanda Y, Nishio Y, Jikihara H, Matsuura N, Murata Y 1999 Role of mitogen-activated protein kinase/extracellular signal-regulated kinase cascade in gonadotropin-releasing hormone-induced growth inhibition of a human ovarian cancer cell line. Cancer Res 59:5133–5142[Abstract/Free Full Text]
230. Lee MT, Liebow C, Kamer AR, Schally AV 1991 Effects of epidermal growth factor and analogues of luteinizing hormone-releasing hormone and somatostatin on phosphorylation and dephosphorylation of tyrosine residues of specific protein substrates in various tumors. Proc Natl Acad Sci USA 88:1656–1660[Abstract/Free Full Text]
231. Gebauer G, Fehm T, Beck EP, Berkholz A, Licht P, Jager W 2003 Cytotoxic effect of conjugates of doxorubicin and human chorionic gonadotropin (hCG) in breast cancer cells. Breast Cancer Res Treat 77:125–131[CrossRef][Medline]
232. Leuschner C, Enright FM, Melrose PA, Hansel W 2001 Targeted destruction of androgen-sensitive and -insensitive prostate cancer cells and xenografts through luteinizing hormone receptors. Prostate 46:116–125[CrossRef][Medline]
233. Hansel W, Leuschner C, Gawronska B, Enright F 2001 Targeted destruction of prostate cancer cells and xenografts by lytic peptide-ßLH conjugates. Reprod Biol 1:20–32[Medline]
234. Beck EP, Vincenti D, Licht P, Berkholz A, Jager W, Lang N, Merkle E 2000 In vitro activity of human chorionic gonadotropin (hCG)–doxorubicin conjugates against ovarian cancer cells. Anticancer Res 20:3001–3006[Medline]
235. Gebauer G, Mueller N, Fehm T, Berkholz A, Beck EP, Jaeger W, Licht P 2004 Expression and regulation of luteinizing hormone/human chorionic gonadotropin receptors in ovarian cancer and its correlation to human chorionic gonadotropin-doxorubicin sensitivity. Am J Obstet Gynecol 190:1621–1628; discussion 1628[CrossRef][Medline]
236. Gawronska B, Leuschner C, Enright FM, Hansel W 2002 Effects of a lytic peptide conjugated to ß HCG on ovarian cancer: studies in vitro and in vivo. Gynecol Oncol 85:45–52[CrossRef][Medline]
237. Miyazaki M, Nagy A, Schally AV, Lamharzi N, Halmos G, Szepeshazi K, Groot K, Armatis P 1997 Growth inhibition of human ovarian cancers by cytotoxic analogues of luteinizing hormone-releasing hormone. J Natl Cancer Inst 89:1803–1809[Abstract/Free Full Text]
238. Kang SK, Choi KC, Cheng KW, Nathwani PS, Auersperg N, Leung PC 2000 Role of gonadotropin-releasing hormone as an autocrine growth factor in human ovarian surface epithelium. Endocrinology 141:72–80[Abstract/Free Full Text]
239. Fuller PJ, Zumpe ET, Chu S, Mamers P, Burger HG 2002 Inhibin-activin receptor subunit gene expression in ovarian tumors. J Clin Endocrinol Metab 87:1395–1401[Abstract/Free Full Text]
240. Steller MD, Shaw TJ, Vanderhyden BC, Ethier JF 2005 Inhibin resistance is associated with aggressive tumorigenicity of ovarian cancer cells. Mol Cancer Res 3:50–61[Abstract/Free Full Text]
241. Zheng W, Luo MP, Welt C, Lambert-Messerlian G, Sung CJ, Zhang Z, Ying SY, Schneyer AL, Lauchlan SC, Felix JC 1998 Imbalanced expression of inhibin and activin subunits in primary epithelial ovarian cancer. Gynecol Oncol 69:23–31[CrossRef][Medline]
242. Ito I, Minegishi T, Fukuda J, Shinozaki H, Auersperg N, Leung PC 2000 Presence of activin signal transduction in normal ovarian cells and epithelial ovarian carcinoma. Br J Cancer 82:1415–1420[Medline]
243. Choi KC, Kang SK, Nathwani PS, Cheng KW, Auersperg N, Leung PC 2001 Differential expression of activin/inhibin subunit and activin receptor mRNAs in normal and neoplastic ovarian surface epithelium (OSE). Mol Cell Endocrinol 174:99–110[CrossRef][Medline]
244. Welt CK, Lambert-Messerlian G, Zheng W, Crowley Jr WF, Schneyer AL 1997 Presence of activin, inhibin, and follistatin in epithelial ovarian carcinoma. J Clin Endocrinol Metab 82:3720–3727[Abstract/Free Full Text]
245. Lau KM, Mok SC, Ho SM 1999 Expression of human estrogen receptor- and -ß, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells. Proc Natl Acad Sci USA 96:5722–5727[Abstract/Free Full Text]
246. Hillier SG, Anderson RA, Williams AR, Tetsuka M 1998 Expression of oestrogen receptor and ß in cultured human ovarian surface epithelial cells. Mol Hum Reprod 4:811–815[Abstract/Free Full Text]
247. Pujol P, Rey JM, Nirde P, Roger P, Gastaldi M, Laffargue F, Rochefort H, Maudelonde T 1998 Differential expression of estrogen receptor- and -ß messenger RNAs as a potential marker of ovarian carcinogenesis. Cancer Res 58:5367–5373[Abstract/Free Full Text]
248. Brandenberger AW, Tee MK, Jaffe RB 1998 Estrogen receptor (ER-) and ß (ER-ß) mRNAs in normal ovary, ovarian serous cystadenocarcinoma and ovarian cancer cell lines: down-regulation of ER-ß in neoplastic tissues. J Clin Endocrinol Metab 83:1025–1028[Abstract/Free Full Text]
249. Cardillo MR, Petrangeli E, Aliotta N, Salvatori L, Ravenna L, Chang C, Castagna G 1998 Androgen receptors in ovarian tumors: correlation with oestrogen and progesterone receptors in an immunohistochemical and semiquantitative image analysis study. J Exp Clin Cancer Res 17:231–237[Medline]
250. Lee P, Rosen DG, Zhu C, Silva EG, Liu J 2005 Expression of progesterone receptor is a favorable prognostic marker in ovarian cancer. Gynecol Oncol 96:671–677[CrossRef][Medline]
251. Akahira J, Suzuki T, Ito K, Kaneko C, Darnel AD, Moriya T, Okamura K, Yaegashi N, Sasano H 2002 Differential expression of progesterone receptor isoforms A and B in the normal ovary, and in benign, borderline, and malignant ovarian tumors. Jpn J Cancer Res 93:807–815[CrossRef]
252. Hamilton TC, Davies P, Griffiths K 1981 Androgen and oestrogen binding in cytosols of human ovarian tumours. J Endocrinol 90:421–431[Abstract/Free Full Text]
253. Chadha S, Rao BR, Slotman BJ, van Vroonhoven CC, van der Kwast TH 1993 An immunohistochemical evaluation of androgen and progesterone receptors in ovarian tumors. Hum Pathol 24:90–95[CrossRef][Medline]
254. Choi JH, Choi KC, Auersperg N, Leung PC 2006 Differential regulation of two forms of gonadotropin-releasing hormone messenger ribonucleic acid by gonadotropins in human immortalized ovarian surface epithelium and ovarian cancer cells. Endocr Relat Cancer 13:641–651[Abstract/Free Full Text]

This article has been cited by other articles:

				A. A. Hakim, C. P. Barry, H. J. Barnes, K. E. Anderson, J. Petitte, R. Whitaker, J. M. Lancaster, R. M. Wenham, D. K. Carver, J. Turbov, et al. Ovarian Adenocarcinomas in the Laying Hen and Women Share Similar Alterations in p53, ras, and HER-2/neu Cancer Prevention Research, February 1, 2009; 2(2): 114 - 121. [Abstract] [Full Text] [PDF]

				S. W. Warrenfeltz, S. A. Lott, T. M. Palmer, J. C. Gray, and D. Puett Luteinizing Hormone-Induced Up-Regulation of ErbB-2 Is Insufficient Stimulant of Growth and Invasion in Ovarian Cancer Cells Mol. Cancer Res., November 1, 2008; 6(11): 1775 - 1785. [Abstract] [Full Text] [PDF]

				K. Johnson Abstract CN02-03: Prospects for targeted reduction of ovarian cancer risk Cancer Prevention Research, November 1, 2008; 1(7_MeetingAbstracts): CN02-03 - CN02-03.

				A. A. Arslan, Y. Gu, A. Zeleniuch-Jacquotte, K. L. Koenig, M. Liu, L. Velikokhatnaya, R. E. Shore, P. Toniolo, F. Linkov, and A. E. Lokshin Reproducibility of Serum Pituitary Hormones in Women Cancer Epidemiol. Biomarkers Prev., August 1, 2008; 17(8): 1880 - 1883. [Abstract] [Full Text] [PDF]

				T. R. Kumar Multiple Ovulations, Ovarian Epithelial Inclusion Cysts, and It'SMAD Two! Endocrinology, August 1, 2007; 148(8): 3591 - 3594. [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Choi, J.-H. Articles by Leung, P. C. K. Search for Related Content PubMed PubMed Citation Articles by Choi, J.-H. Articles by Leung, P. C. K.